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Pharmaceutical drugs are one of the most socially important heath care products.  
They are part of many individuals’ everyday lives, from the eradicating of diseases at 
birth to treating patients at the end of life. However, for many patients access is 
prevented due to expensive cost.  This study explored cost-related non-adherence 
(CRN) and researched if reimportation of pharmaceutical drugs from other countries 
could increase patient drug adherence. The perceptions of 10 patients and 10 
providers in Maine were assessed. Maine is the only state that allowed its citizens to 
purchase prescription drugs from abroad.  The research questions addressed (a) how 
reimportation drugs could contribute to drug adherence, (b) the perceptions of 
patients, and (c) the perceptions of key providers of reimportation. This study was 
guided by a theoretical framework utilizing Kurt Lewin’s theory of organizational 
change.  Participants answered 15 open-ended questions. The study utilized a 
qualitative grounded theory approach; data were analyzed inductively. The research 
demonstrated that patients and healthcare providers had positive perceptions for a 
reimportation policy. Future research of other regions for this topic should prevail.  
 Member checking was used to validate the emerging theories of increased long term 
drug adherence incentivized by affordable drug cost, which contributes to perception 
of competence, better management of current disease, and decreased safety concerns.  
Positive social change implications can be achieved through savings to the health-
care industry by creating a pathway to affordable drugs that will bring more drugs to 
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 Per capita expenditures for prescribed drugs are much greater in the United States than 
other developed nations.  The United States’ population for cost related non-adherence (CRN) 
are doubled that of Canadian residents (Kennedy & Morgan, 2009). Kanavos, Ferrario, 
Vandoros, and Anderson (2013) found that brand drug prices increased from 5% to 198% in the 
United States within the past decade. According to a 2013 survey by Health Affairs, drug prices 
in the United States are so high that more than 50 million American patients (21%) are currently 
skipping doses or never getting the prescription filled (Cohen,Whitney, Kirzinger and Gindi 
2013).  Patients often skip doses in an attempt to save money; however, this tactic is most likely 
to increase personal healthcare costs (Cohen, et al, 2013). 
 Stuart (2014) suggested that increased pharmaceutical spending is partially due to the 
rapid uptake of newer and more expensive drugs in comparison to other nations. For example, 
Celebrex (a nonsteroidal anti-inflammatory drug used for the treatment of pain or inflammation) 
has an average cost of $225USD in the United States, which is twice as much as the cost in 
Britain ($112USD) and four-times as much as the cost in Canada ($51USD). Higher prices for 
mandated prescription drugs lead to prescriptions not being filled (Stuart 2014). Therefore, cost 
is a contributing factor to patients’ non-adherence (Khatter & Dickens, 2006). In particular, 
retired, senior citizens may experience a lapse in Medicare insurance coverage and leave 
prescription drug request unfulfilled (Khatter & Dickens, 2006).  
 The purpose of this research was to analyze the perceptions of Maine citizens with 
chronic diseases and recurring prescription drug refills concerning reimportation of 
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pharmaceutical drugs. State legislation allowed low-cost drugs to be reimported. The overall 
effects of this policy were also analyzed. In this chapter, I discuss the background, problem 
statement, research questions, hypotheses, theoretical framework, nature of the study, definitions, 
assumptions, scope/delimitations, limitations, and significance of the study.  More importantly, I 
discuss the implications for positive social change and how savings to the healthcare system and 
patients can ensue; while giving increase accessibility to much needed expensive medications. 
Social, health, and economic costs of chronic disease management are high and knowledge about 
potentially greater and cheaper access to prescription drugs can improve the overall health of the 
individual and community.  
Background 
 
 According to the Alliance for Health Reform (2006) reimportation of prescription drugs 
has gained momentum in the political discourse. Having other incentives in place to help 
supplement expensive drugs (such as Medicaid Part D) is needed. Thus, other alternatives 
measures are required; reimportation of medication drugs could be one of those alternatives.  
Views on reimportation are polarized (safe for U.S. citizens or not safe for citizens) amongst 
those who support and oppose this measure with both sides attempting to justify their voices 
(Bhosle & Balkrishnan 2007). The Medicine Equity and Drug Safety Act of 2000 (MEDS Act) 
allowed certain institutions to reimport U.S. manufactured, and Food and Drug Administration 
(FDA) approved drugs, exported outside the United States back into the United States at a 
discounted price (Bhosle & Balkrishnan 2007). However, because of the lack of approved votes 
in Congress by the Department of Health and Human Services (HHS) the MEDS Act was 
terminated in December 2000 (Bhosle & Balkrishnan, 2007). The opposing concern for 
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reimportation is safety.  According to former Secretary of Health and Human Services, Donna 
Shalala, prescription drugs that are made in the United States, shipped overseas, can safely be 
reimported (CDC.gov, Retrieved 2015). Former Secretary Donna Shalala stated that the FDA 
can monitor the safety of drugs coming back into the United States for $24 million more in the 
budget in order to increase inspection services (Kaiser Health, 2009).   
  Ho, Bryson, and Rumsfeld, (2009) stated as a result of high drug prices and the need for 
less expensive drugs there is a system within  healthcare that contributes to patients 
nonadherence to drug medication. There are many studies exploring nonadherence. Many 
chronic diseases have been researched for patients’ nonadherence levels (Brown & Bussell, 
2011). Medication nonadherence has been a growing concern to healthcare providers and other 
stakeholders due to increased evidence that it is linked to adverse reactions and increased long-
term healthcare costs (Ho et al, 2009).  
 Diabetes is a chronic disease that is prevalent throughout the nation and regionally in 
Maine. According to the Centers for Disease Control (CDC), (2014) undiagnosed and diagnosed 
diabetes in the United States totaled 29.1 million citizens or 9.3% of the population having 
diabetes. Diagnosed population consisted of 21.0 million people and undiagnosed consisted of 
8.1 million people; also 27.8% of citizens with diabetes are not diagnosed. According to the 
official Maine website (Maine.gov),(2014) diabetes is one of four contributing diseases to the 
state’s mortality rate. It is imperative to investigate options to decrease mortality rates and 
improve quality of life. Affordable medication from other markets would allow for exploration 
of patients’ adherence levels.  This research gave researchers, healthcare officials and others, 
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data (not seen in any other regions of the country) options, and corrective measures needed for 
patients’ ability to maintain physician’s guided drug regimen. 
Problem Statement 
 
 A plethora of research literature exists on patients’ medication non-adherence practices. 
There also exists literature on cost determinants of drugs and affordability. But literature gaps are 
present in terms of research providing data concerning reimportation of drugs as one corrective 
measure to patients’ mandated drug regimen. This is in part because of the current policies and 
the federal government denial of reimportation drugs into the United States’ markets.  Therefore, 
research is needed to understand the impact of reimportation on non-adherence drug regimen. 
Accomplishments of this study can be obtained by studying the one state that has legislation in 
place. Healthcare officials, politicians and others are then allowed to evaluate the perceptions of 
Maine’s population as they are free to reimport medication.  
 The research study explored the link between patient drug nonadherence and 
reimportation of drugs. Utilization of a qualitative approach allowed for the experiences, 
opinions, and feelings of the informants to form a hypothesis. Increasing supply and opening the 
market to other countries will bring more prescriptions to market.  Purchase of prescriptions 
drugs at a lower cost from a different market through reimportation will render immediate 
savings that may contribute to increased drug adherence. 
  According to Kennedy, Coyne, Joseph and Sclar (2004) a small but increasing 
population of United States’ citizens are unable to purchase medications that are prescribed to 
them. Cost-related nonadherence is similar to other health care access issues; it is not evenly 
distributed among the population. Senior citizens on fixed incomes often make the decision to 
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purchase food or purchase their monthly prescription drugs (Carrns, 2012); as a result, drugs are 
not taken or prescriptions are not filled at all. Chronic illnesses continue to get worse, and higher 
healthcare treatment cost ensues. The change in locations of drug purchases significantly 
decreases the cost. Citizens given the opportunity to save a tremendous amount of money on 
prescription drugs could experience enhanced long-term healthcare benefits due to their ability to 
purchase and comply.  Cleemput and Kesteloot (2002) stated that it is an important factor of 
impediment to the effects of health interventions; gaps exist between efficacy and effectiveness 
due to non-compliances. Research is needed to explore if reimportation of medication drugs and 
the effects of reimportation have an effect on patients’ adherence. It may contribute to decreasing 
long-term healthcare cost and improve the disease state of patients. 
 The purpose of this proposed research was to explore one component of patient non-
adherence of prescription drugs (CRA) and investigate if reimportation policies will enhance 
drug adherence among the Americans with chronic diseases. The study looked at non-adherence 
due to CRA that causes patients to skip dosages or not fill the prescription at all. Newly 
implemented policies in the state of Maine have adopted reimportation drug laws for its citizens. 
The study assessed the perception of this population in relationship to the newly implemented 
reimportation law in the state of Maine.  
Purpose of Study 
 
  The purpose of the study was to determine the perceptions and explore the influences of 
drug reimportation policy on chronic disease patients in the state of Maine. This new legislation 
was selected for its uniqueness within the United States. The research attempted to further 
demonstrate optional corrective measures for patients’ medication regimen and interpret the 
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perceptions of the participants from the data collected. It is the desire of this research to 
contribute data on a national scale that could be replicated in other states. 
Research Questions 
 Research questions were formulated to correspond to interview questions in order to 
capture patients’ and provider’s perception of this process.  The questionnaires/interviews were 
designed to address the following research questions: 
 RQ1: How does a reimportation prescription drug policy contribute to patients’ drug 
 adherence? 
 RQ2: What perceptions do patients have about reimportation drugs as related to a  chronic 
 disease? 
 RQ3: What are the perceptions of key providers (physicians, physician assistants   
 & nurse practitioners) regarding the impact of reimportation drug laws on patient 
 medication adherents? 
Theoretical Framework 
 
 The U.S. government has many layers of political management thereby creating a 
complex bureaucratic process. This can lead to frustration from the general population and the 
willingness for change is diminished. There is a need for new and better legislation from political 
officials and for better internal processes. Kurt Lewin’s (1947) theory of organizational change 
proposes a thought process that could be utilized. Kurt Lewin’s previous works consisted of 
studies within leadership and various effects of leadership (Burnes, 2004). Morrison (2014) 
noted that Lewin focused his attention on group based decision-making, developing the force 
field theory, unfreeze, change and refreeze change management models with action research, and 
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the group approach to training dynamics. With a focus on three distinct stages of change 
management: (a) unfreezing, (b) change (transition), and (c) refreezing he suggested unfreezing 
is the method that involves locating a process to make possible for people to relinquish 
counterproductive old habits and patterns.  
   Unfreezing is needed to overcome the levels of resistance and group conformity that 
allows for moving to a new stage or changing movement. Secondly, change/transition is needed 
to have change in thoughts, feelings, behaviors, or all three that results in liberation, and increase 
productivity. Lastly, refreezing is putting into place the newly accepted changes into a new 
accepted habit; it now becomes standard operating procedure (Morrison, 2014). It is possible to 
revert to the old habits without this implementation. Adaptation and implementation of new 
policies is built upon this framework. Organizations, leaders, and others must acknowledge a 
new mindset which is imperative to employ new national legislation related to prescription 
drugs. Many processes and strategies could increase the chance of health policies and programs 
to be adopted and enforced within formal institutions (Kritsonis, 2005). 
Nature of Study 
 
 I explored the perception of individuals residing in Maine in order to determine if the 
reimportation policies have any effect(s) on patients’ perceptions of medication adherence.  In 
my research I used semi-structured questionnaires/interviews to produce data on a sample 
participant pool diagnosed with a chronic disease.  
 As a joint venture, physicians and patients must communicate concerns of the drug 
regimen, therefore, it is necessary to query healthcare providers on their assessment, perceptions 
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and experiences with their patients.  Patients and providers are able to provide new insight on the 
effects of the reimportation policy.  
Definition of Terms 
 
 Reimportation: The importation of goods into a country which had previously been 
exported from that country (http://www.merriam-webster.com, Retrieved, 2014). 
 Adherence: the obedience of the patient to the medical advice (http://www.merriam-
webster.com, Retrieved, 2014). 
 Non-adherence: a lack of adherence (http://www.merriam-webster.com, Retrieved, 
2014). 
 Federalism: a system of government suggesting sovereignty is constitutionally divided 
between a central governing body and constituent political sub-units (states or provinces) 
(http://www.merriam-webster.com, Retrieved, 2014). 
 Proclivity: often choosing or do something regularly; an inclination or predisposition 
toward a particular thing (http://www.merriam-webster.com, Retrieved, 2014). 
 Chronic Disease: along lasting condition that can be controlled but not cured 
(http://www.merriam-webster.com, Retrieved, 2014). 
 Drug Tiers: categories in which drugs are assigned to one of four or five category 
sections (copayment or coinsurance tiers), based on medication usage, clinical effectiveness and 
cost (Blue Cross-Blue Shield [BCBS], Retrieved 2014). 
 Grounded Theory: consist of a theory that is inductively formulated from work gathered 
in the field from real world experiences, emerging from researcher’s interviews and 




 Qualitative researchers assume deep understanding and rich description are indication of 
the methodology.  This research study believes reality is looked upon as subjective and that 
environments of social realms are personal constructs generated by individualism and are not 
generalizable (Velez, Retrieved 2014). These thoughts are grounded in constructivism and not 
positivism.  It is assumed not to be a generalizable reality that is quantifiable for larger 
populations.  Qualitative researchers also believe that exploration is guided and developed by the 
values of the researcher along with the hypotheses, theories or the framework being utilized. 
 Context is crucial, and one can assume that without an exquisite comprehension of the 
contextual nature of an exploration project the investigative data cannot be categorized as 
generalizable (Sechrest & Sidani, 1995).  Pluralistic, interpretive, and open-ended is the desire, 
along with contextualized perspectives (Creswell & Miller, 2000). The integrity of this research 
was built upon a platform of trustworthy responses from the informants; it was the assumption 
that participant’s willingness to participate in this study will result in veracious responses. 
Limitations 
 The study is limited to a population from only one state. The state of Maine is the least 
dense state in the Northeast region of the United States and ranks 2nd behind Vermont as having 
a population predominantly of Whites, 95% (Long, 2012).  Therefore, the study does not 
represent other entities of race and demographic regions. With a focus on chronic disease 
patients, the study cannot theorize for the experiences of participants having various other acute 
diseases. Therefore, nonadherence and reimportation effects and perceptions of these diseases 
remain to be seen. Maine’s new reimportation policy and implementation tenure are short (only 1 
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year) and perhaps not enough time has passed by to see the true effects of this legislation. It is 
possible that this research could yield additional and beneficial data by repeating the research 
study in 2-4 years into the future. 
Significance of the Study 
 The research is timely since it allowed access to a population (Maine) that is first and 
only in the nation to adopt such reimportation drug policies. As of October 2013, Maine has a 
population of approximately 1.3 million citizens.  This equates to approximately 41.3 citizens per 
square mile, making Maine the least dense state in Northeast region (Census.gov, Retrieved 
2014). The majority of Maine’s population (75%) dies from just a few chronic diseases: cancer, 
diabetes, chronic lung disease, and cardiovascular disease (CDC, 1994). These diseases also 
cause major disabilities.  On a national scale, 1out 10 Americans suffers from these four chronic 
diseases (CDC, 1994). Research is needed to explore options to assist patients with chronic 
diseases in order to provide better living conditions now and long-term. 
  Significant knowledge could be gained from this population that can be replicated 
nationwide.  This proposed study included data from a population on nonadherence of 
prescription drugs and the reimportation policy effects. The results of this study presented new 
data not seen by any other state because of null reimportation policies.  The state of Maine is 
precedent in this manner and this research study has presented new data, new insight to drug 
reimportation. Also, allowing for continued dialog of the topic with the intent to generate 







Scope of Study/Delimitation 
 
 The research study was conducted with adult, chronic disease patients and providers with 
access to the new reimportation policy in Portland, Maine (patients) and state-wide (providers). 
Adults with an age range of 18 years old and older were solicited; conformation of age was 
achieved via demographic profiling within the research questionnaire apparatus. The research 
had a total of 20 participants: 10 patients and 10-providers.  The adult participants were 
diagnosed with a chronic disease and have a continuous regimen of prescription drug refills. 
Healthcare providers such as physicians, nurse practitioners, and physician assistants were given 
questionnaires for their perceptions of this policy. The exclusionary and inclusionary decision 
process performed during the development of the study identified boundaries of the research 
topic. The initial delimiting step was choosing the research topic, implying that all other related 
research concerns have been rejected. Both genders men and women were considered and a 
diagnosed with a chronic disease was confirmed. The apparatus used to collect data was 
questionnaires/interviews; these questionnaires were used to make several distinctions. The 
geographical placement of the study is unique and can only be performed in one locale (Maine). 
Therefore, it was critical to visit Maine to capture vital information and observe non-verbal cues 
that cannot otherwise be observed.  
Implications for Social Change 
 
 Pharmaceutical drugs are the most socially important healthcare product, having 
influences in every healthcare facet. As of 2012, the United States had 312 million citizens 
(Census.gov, 2014). Most individuals will be affected by pharmaceutical drugs at some point in 
their lives.  From time of birth and throughout life, drugs play an important role for good health 
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and enhancement of quality of life.  Childhood immunizations have eradicated many previously 
life-threatening diseases, and individuals continue to use drugs throughout their lives. The entire 
population is affected directly and indirectly. Cost-related nonadherence is a significant factor 
for continued health problems and rising healthcare costs. Consumers of any product or service 
will typically make the most economic, cost saving decision before making a purchase; drug 
purchases are no different. Keeping reimportation in the forefront can allow for many officials, 
various healthcare departments to unite and figure out a logistical process for ensuring safety and 
quality. Reimportation drugs can surmount to a healthier population while contributing to a 
significant savings to the healthcare system. 
 This research study addressed real-world applications within the healthcare arena. It 
contributes to strategies that can be implemented to enhance patient adherence of their drug 
medication regimen.  As seen in the state of Maine, this research desired to foster new dialog that 
contributes to national policy change. With current national policies and the continuous high cost 
of drugs, there exists a social problem that has been greatly overlooked.  The action of 
reimportation (as a contributing remedy to increasing adherence) will significantly contribute to 
positive social change to a population which relies on these drugs but have limited access due to 
the significant high cost. Reimportation policies can have a significant impact on healthcare 
prescription savings with long-term health care savings, due to drug adherence.  This increase 
adherence can decrease chronic diseases from getting to a worsen state, that requires additional 






 Due to the social economics, cultural and the structure platform of the pharmaceutical 
industry (its ability to control pricing) the United States’ healthcare system has created and 
sustained cost-related nonadherence that has contributed to an increasingly worsen state for 
chronic disease patients. Their inability to afford much-needed drugs has forced patients to not 
adhere to physician’s orders for medication regimen. Unfortunately, the outcome results in 
higher medical costs, decrease quality of life and an issue that is perpetuated without any resolve. 
Senior citizens are affected more due to their social economic status and insufficient medical 
insurance coverage.  The general population will (in time) demand safe, affordable drugs whilst 
current policies are deficient in delivering the demands of a nation. Organizational change is 
needed to create and sustain safe new policies while changing the mindset of political officials 
and healthcare officials granting patients safe and cost saving drugs which may contribute to 
their ability to become increasingly adherent. 
 The literature review in Chapter 2 presents details of factors contributing to drug 
nonadherence, cost comparisons, contrasting information on the European pharmaceutical 
system and reimportation concerns and details. In Chapter 3, I described detail of the design for 
the research study using qualitative grounded theory methodology.  Chapter 4 outlines the results 
of the data collected from participants in Maine.  I presented the results of memoing, opinions, 
feelings, and perceptions of the informants.  In Chapter 5, I presented and explained the findings 











 Several studies have been performed in relationship to patients’ non-compliance of their 
prescription drugs regimen. Also, existing is a plethora of data (pros/cons) for reimportation of 
prescription drugs.  Current federal laws of the United States will not allow any state to reimport 
prescription drugs; therefore, research has been quite limited. But the situation is changing, a 
new ruling (first of its kind) in the state of Maine allows direct purchases of mail-order drugs 
from foreign pharmacies (Levitz & Martin, 2013). The new policy took effect in October 2013. 
Literature gaps are present regarding research concerning reimportation of drugs as one 
corrective component to patients’ mandated drug regimen. This research explored this topic and 
provided research data to the study. 
 Research is needed to understand and explore the impact of pharmaceutical reimportation 
drugs in relation to patients’ non-adherence conduct; accomplished by studying the one and only 
state that has legislation in place. Maine’s population is free to reimport pharmaceutical 
medications and does not have to participate in any clandestine activities or be in fear of punitive 
repercussions. Thus, there exists a completely different mindset among this population (that is 
not found in other locales) that could render valuable information on the topic.  
 The purpose of this study was to research the perceptions of drug reimportation policy on 
chronic disease patients in the state of Maine and the influences of said policy as it relates to 
drug adherence.   The study further explored optional corrective measures for patients’ 
medication regimen and interpreted the perceptions of the participants from the data collected. 
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 This chapter discussed the demographics of Maine’s population, local and national 
diabetes prevalence, and reimportation current stance. Additional discussion consisted of 
adherence measurements, and a specific population who is having difficulties filling 
prescriptions. Medicare Part D along, with a preventive healthcare model is discussed. Further 
discussion of drug cost determinants, long-term health costs, and a brief overview of the 
pharmaceutical industry while addressing some political voices, FDA rulings and gaps within the 
literature. 
Literature Review Proper 
 Non-adherence is a topic of heavy discussion within the healthcare arena. It is a key issue 
concerning the plight of patient care. Patients often state more prescription use (adherence) to 
their physician than what actually occurs (Karmel, 2005). In a compliance study performed by 
Dr. Michael Kass (published in 1986) he discovered a large discrepancy between self-reported 
adherence 100% and the true value of 76% (Karmel, 2005); and the problem still persists today. 
Most patients blame the increased cost of drug as the problem for their non-adherence; this is 
known as cost-related non-adherence (CRA). 
Some reports for reimported drugs thus far are indicating significant savings to the 
citizens of Maine. For example, utilizing a Canadian broker (CanaRX) the city of Portland, 
Maine pays approximately $200.00 for a 3 month supply (with no co-pay) of Nexium; Nexium is 
a heartburn medication regulating at a 40 mg dose per tablet. The same exact Nexium medication 
through Aetna Insurance Inc. (USA) is at $620.00 and has a co-pay of $156.00 (Levitz & Martin, 
2013); that is a savings of $576.00 to the patient and the healthcare system. Many other 
16 
 
medications fall under similar savings, therefore, the overall cost savings to the healthcare 
system would be enormous. 
Karmel (2005) looked at a meta-analysis of 569 studies that observed prescriptions of 
non-psychiatric physicians, this study had a 25 % non-adherence rate; the study also revealed a 
30% non-adherence rate for silent conditions such as diabetes and pulmonary diseases that 
demanded long-term and complex drug regimens. This research study focused on the chronic 
disease patients for Maine’s population and their nonadherence conduct. Early reports from 
Maine are already indicating cost savings. A spokesman for a private firm in Maine has stated 
that access to international pharmacies has reduced its annual health-care spending cost up to 
$600,000 (Levitz, 2013). 
Because of the esoteric nature of Maine’s policy and its genesis stage, I explored various 
factors that would yield information on the pharmaceutical industry, the political arena, and 
culture and socioeconomics aspect of reimportation.  The literature mining also explored long-
term cost saving, the federal law stance and briefly contrasted foreign pharmaceutical markets to 
the United States markets.  
Literature Search Strategies 
A search of several electronic databases with respect to patient drug non-adherence, and 
drug reimportation included Google Scholar, Proquest Health and Medical Complete, Proquest 
Central, EBSCO, ERIC, Medline, Government websites (FDA, CDC and others) various 
university school libraries and the reference section of reviewed articles; all terms were entered 
into each database. Keywords and phrases used within each database included; patient drug 
compliance, patient drug non-compliance, patient drug adherence, patient drug non-adherence, 
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reimportation bill, Maine reimportation law, and chronic disease; Canadian exports of drugs, 
drug tiers, pharmaceutical intellectual property, preventive healthcare, European 
pharmaceutical markets, generic drugs, reimportation safety, grounded theory and FDA 
reimportation. 
Basic economics can justify decreased pricing of products and services when consumers 
are given a choice, and competitive markets are applied. Applying this theory to the 
pharmaceutical system and making a connection that increases patient drug adherence has yet to 
be seen. And, this is not surprising because the (United States) has not allowed legal 
reimportation of any pharmaceutical drugs thereby studies of reimportation drugs and patients’ 
adherence are void and null. Literature of variables, reimportation and adherence, is not 
supported within the literature review.  Thus, it is imperative to capture data and study this new 
policy and learn of the affects it is having on a given population. 
Gaps in Literature 
 Research literature exist on patient drug adherence and non-adherence; there also exist 
literature on cost of drugs and the affordability (or the lack thereof) but there are literature gaps 
concerning research that provide a link to reimportation of drugs as a corrective measure for 
patients’ non-adherence. Literature gaps are to be expected due to the current policies and the 
denial of reimportation drugs into the United States. It is imperative to explore the only state that 
has policies in place for reimportation of pharmaceutical drugs. 
 Asking if and how reimportation affects patients’ adherence is completely valid, it has yet 
to be determined. The literature is void to null on the affects (if any) that these variables have to 
each other.  It is the hope of this research that federal enforcements (FDA & others), lawsuits and 
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any other antagonistic efforts do not interfere with reimportation efforts and that this topic can be 
transitioned to other states. The tempestuous discussions of reimportation should keep the topic 
in the forefront of political officials and the general public.  
 Pharmaceutical drugs (without a doubt) are the most socially required healthcare 
products.  The integral role affects every facet of healthcare and the quality of life for patients; 
this is evident from the many diseases that have been eradicated by drugs that previously killed 
many individuals worldwide (NAPSRx, 2013). Cleemput and Kesteloot (2002) stated that non-
adherence is an important factor of impediment to the effects of health interventions; gaps exist 
between efficacy and effectiveness due to non-adherence. 
This qualitative study explored the perception and mindset of individuals who were once 
clandestine in their efforts to acquire inexpensive drugs from foreign markets and what affects 
are being displayed with this new found freedom. Therefore, many gaps exist and much 
knowledge awaits future researchers who take on the pharmaceutical industry and challenge 
them to provide more affordable drugs and keep in mind the financial distresses that many social, 
and economic hardship patients have. 
Theoretical Foundation 
 This exploration is built upon Lewin’s (1947) theory of organizational change. It 
proposes a thought process that could be utilized for federalism change. Kurt Lewin (1890-1947, 
social psychologist) whose work involved studies of leadership and their effects that focused on 
three distinct stages of change management: (a) unfreezing, (b) change (transition) and (c) 
refreezing he suggested unfreezing is the method that involves locating a process to make 
possible for people to relinquish old habits and patterns that proved counterproductive.  
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   Levels of resistance and group conformity must be unfrozen in order to allow forward 
progression to a new stage; thereby incorporating change (transition) in thoughts, feelings, 
behaviors, or all three that result in liberation and increase productivity. Lastly, refreezing puts 
into place the newly accepted change into a new accepted habit. It now becomes standard 
operating procedure (Morrison, 2014). It is easy to revert to the old habits without this 
implementation of refreezing. Adaptation and implementation of new policies is built upon this 
framework. Organizations, leaders, and others must acknowledge a new mindset which is 
imperative to employ new national legislation related to prescription drugs. Many processes and 
strategies could increase the chance of health policies and programs to be adopted and enforced 
within formal institutions (Kritsonis, 2005). 
Demographics-Maine 
 
As of 2013, Maine had a population of approximately 1.3 million citizens; this equates to 
approximately 41.3 citizens per square mile, making Maine the least population-dense state in 
Northeast region (Census.gov, 2014). Maine’s age-distribution is somewhat out of balance stated 
Professor Colgan an instructor at the University of Southern Maine’s Muskie School of Public 
Service (Colgan, 2014); the oldest national status shows a median age of 43.5 y/o according to 
2012 U.S Census Bureau; this is an indication that half of Maine’s population is older than 43.5 
y/o and half is younger. 
 Maine trails only the state of Vermont in having the lowest percentage of citizens under 
the age of 18. The Census department estimates that Maine has approximately 411,540 citizens 
between ages of 45 and 65 while another 301,124 citizens are between 20 and 39 years of age 
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(Census.gov, 2014). In 2011 and 2012 for the first time in 70 years, more people died in Maine 
than were conceived according to Maine’s Office of Vital Records (Maine.gov, 2014). 
High Disease Prevalence 
 
 Seventy five percent of Maine’s population dies from four chronic diseases: chronic lung 
disease, cardiovascular disease, diabetes, and cancer (CDC.gov, 1994). Maine’s chronic disease 
prevalence is in alignment with national levels.  According to the CDC, as of 2012, 
approximately 50% of adults (117 million people) have one or more chronic disease(s) health 
conditions. Over a fourth of adults have two or more chronic health conditions.  Seven of 10 
reasons of death in 2010 were related to chronic diseases. Heart diseases and cancer combined 
accounted for nearly 48% (half) of all deaths (CDC.gov/chronic diseases, 2014) and diabetes is 
the primary cause of kidney failure that often leads to death. In addition to killing 75% of 
Maine’s citizens, these diseases also cause major disabilities.  This is comparable to the national 
scale; for 1out of 10 Americans. These four chronic diseases contribute to limitations of daily 
activities (CDC.gov, 1994). Therefore, it is significant to research options that can alter the plight 
of patients’ living conditions now and long-term. 
Diabetes Maine 
 
Although the research consisted of patients with various chronic diseases, diabetic 
patients display high numbers of non-adherence in the United States and regionally in the state of 
Maine. Prevalence of pre-diabetes has remained steady yet diabetes among the population of 
Maine has steadily increased over the years staying in line with increase rates of the United 
States (Maine.gov, 2014). Utilizing data from the Maine Behavioral Risk Factor Surveillance 
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System (BRFSS) data is collected from random adults with chronic related diseases and injury; 
each year over 6,500 Maine adults participate in this survey (CDC.gov, 1997). 
 Pre-diabetes among males and females are very similar for survey years 2008 to 2010 
(Maine.gov, 2014). According to state records, 7.4% of its population has diabetes; this ranking 
is 20th of 51(among other states); that equates to 6.6 adults out of every 100 adults having 
diabetes. Furthermore, for every 100,000 citizens there were 27 deaths related to diabetes in 
2002 (CDC.gov, 2014). 
Diabetes Type II 
 
 WHO (2003) suggested poor adherence to the regimen for diabetes resulting in avoidable 
pain and suffering for patients that translates to excess healthcare cost. In a World Health 
Organization study in Europe, only 28% of patients treated for type 2 diabetes achieved good 
controlled glucose levels (WHO.gov, 2003).  The study stated that the control of diabetes 
requires more than consumption of medicine, suggesting that change of diet, monitoring of blood 
levels and eye examinations are required. In contrast, the study noted that in the United 
States<2% of adults with diabetes performed the full level of care as reported by the American 
Diabetes Association; among one of the reasons for this was economic costs (WHO.org, 2014). 
United States Reimportation Bill (2000) 
 
 Competing proposals to aid Medicare beneficiaries pay for medicine (Dewar, 2002) is an 
ongoing discussion. The process of allowing drugs produced in the United States, to be shipped 
out of the country and returning to its origin (reimportation) remains elusive in today’s 
healthcare system.  Current legislation remains inactive and necessitates certification from the 
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Health and Human Services Secretary (HHS). Until such processes, the United States will be 
devoid of cost benefits and savings to the healthcare system from a national reimportation policy. 
Federal Drug Administration/Federal Ruling 
 
Several safety concerns are noted within the import revision of the Federal Food, Drug, 
and Cosmetic Act (FFDCA) that vigorously limit types of drugs that can be imported into the 
United States. Several concerns from the FDA exist; for example it is unclear whether overseas 
pharmacies exporting prescription drugs would follow the United States’ federal laws that 
protect privacy. Under any proposed mandate, states have no mechanism in place to ensure 
foreign pharmacy compliances, thus physicians, pharmacists, and patients are unable to judge 
properly whether products are safe and effective (FDA, 2014). 
The FDA is also concerned with labeling of products and a lack of logistical recall 
procedures in place; there are no practices to ensure that only FDA approved products are 
shipped. Several other concerns are listed, and discussions for each can be quite overwhelming 
yet many believe that now is the time to take a closer look at reimportation. 
United States Pharmaceutical Industry/Intellectual Property 
 
 Arfwedson (2014) suggested that reimportation is the protocol whereby drugs are 
protected by intellectual property rights (IPR); for example patents, copyright or trademark) and 
these drugs are placed into market circulation and then reimported to another market (without 
authorization of owner). The argument extends to both sides of the aisles with some stating that 
the reimportation undermines intellectual property that decreases re-investment opportunities; 
while others state the decreasing cost of reimportation drugs benefits their citizens.  Intellectual 
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property rights (IPR) (although limited) are conveyed by the state for certain ideas, expressions-
products of intellect. 
 Because IPR is conveyed by state mandates, their existence has limited barriers that are 
bound by a geographic barrier. But many states implement “principle of national exhaustion” 
that states IPR holder’s rights are extinct upon first sale within national borders. In contrast, 
international exhaustion terminates rights upon first sale anywhere and reimportation may not be 
excluded (Arfwedson, 2014). Exhaustion policies vary in many ways and within different 
countries. 
In the United States, the first sale mantra applies when purchased outside a vertical 
distribution chain (Thomas, 2007). Reimportation of pharmaceutical drugs are admissible, in 
order to block and trademark owner needs to show that imports are not identical in quality to the 
original products. Currently, there is no legally binding global consensus pertaining to 
exhaustion of intellectual properties. The closest concept we have to a global agreement is the 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) that is govern by the World Trade 
Organization; TRIPS provides very limited intellectual rights standards therefore limited 
protection (WHO.org, 2014). 
Pharmaceutical Lobbyist-Opposition 
 
 With such large profits, it is no surprise to see drug companies in opposition for new 
policies that would infringe upon their closed markets.  Hess (2002) indicated that The 
Pharmaceutical Research and Manufacturer of America (PHrMA) has voiced its opposition to 
reimportation. He (Hess, 2002) also stated that the drug industry has spent well over $40 million 
to dispute new legislations that could promote reimportation. Senator DeLauro (D-Conn) stated 
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that current policies allows drug manufacturers a way around the processes that undermines the 
entire system (Hess, 2002)  due in part to having a strong representation (lobbyist group) 
assembled in Washington D.C. 
Reimportation National Stance-In Favor 
 
 Reimportation of prescription drugs continues to gain national support at various political 
levels; a system called reimportation due to many products origins and is produced in one locale 
(country), shipped to another locale (outside the country) and is then returned to original locale 
where it is sold at a discounted price.  Broader reimportation legislation was addressed yet one 
caveat to this legislation (within the body of the policy) was that it must be certified by a sitting 
Human Health Secretary (HHS). Former Human Health Secretary Donna Shalala did not certify 
it therefore (reimportation policies) never took effect (Lueck, 2002); there exist an inactive, non-
enforceable law on the books as it relates to reimportation. Many Americans fail to realize that 
such a bill exist and was (also) signed by former President George Bush but again certification 
from then Secretary of Health and Human Services Tommy Thompson eluded the process and 
the non-certified process has repeated up to current day thus, no national reimportation policy. 
 Arias (2003) stated that Canadian processes for labeling, distribution and handling 
prescription drugs are safe and also stated that in many instances the process was even safer than 
the United States. Outspoken leaders from both sides of the aisle agree that safety must come 
first. Arias (2003) noted that the cost comparison of drugs between Canada and the United States 
are quite substantial. Several leading companies in the private sector are advocates for such 
measures, for example, The America Association of Retired Persons (AARP) has long favored 
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reimportation as they showed support for a bipartisan bill introduced by Senators Snowe (R-ME) 
and Senator Stabenow (D-MI) (Moscovitch, 2011). 
One of the largest pharmaceutical retail distributors (CVS) has also indicated support for 
reimportation.  CVS (based in Rhode Island) operates over 4,100 pharmacies nationwide; they 
were the first major drug store chains to support drug reimportation (Ryan, 2004). High ranking 
officials in many states also have stated their support for this matter and some 20 state attorneys’ 
general in various regions has indicated high support for drug reimportation.   Other supported 
documentation has been established by Representative Ron Paul, his bill indicates a possible 
savings of nearly $20 billion from the Congressional Budget Office with the implementation of 
drug reimportation (Congress.gov, 2014). 
DeAgostino (2004) stated that a reimportation bill would pose no safety risk and that the 
reimportation in Europe is very common and safe; facts indicate that reimportation of drugs has 
been done for over 20 years in Europe. The United States’ healthcare system has made attempts 
to soften the high price of medication but to no avail. Democrat Kernan and Republican Daniels 
support drug reimportation if the government is unable or unwilling to curb high prices. 
 Because of high prices, many cities throughout the nation are considering looking to 
Canada for prescription drugs. Boston Mayor Thomas Menino announced a pilot program that 
will lower cost of over 7,100 employees and retirees of the state (Austin American-Statesman, 
2003). The state of Minnesota is setting up a website while West Virginia and Illinois look to 





Reimportation National Stance-Against 
 
 There is no shortage of contrasting voices on reimportation, many officials have a 
common say in the matter and safety is the main concern. Former Department Health and Human 
Services Secretary Tommy Thompson stated that he could not vouch for the safety of drug 
imports and felt that any savings would be limited (Dalmia, 2003). Further discussion suggests 
that removing protection barriers for drugs could invite U.S. patients to counterfeit, dangerous 
medicines, and adulterated drug products (PR Newswire, 2000).  For every region of political 
representation there are those who oppose reimportation; many political officials echoing the 
voices of the people in their political regions.  
            Safety concerns continue to block efforts to streamline drug reimportation programs 
Arias, (2004). Officials agree that safety must come first when purchasing prescription drugs. 
Speaking to the U.S. Newswire Dr. Matthews stated reimportation is a safety issue but also 
suggested that it is a job issue as well. Local communities across America would suffer due to 
the outsourcing effects reimportation has on local economies. 
Reimportation-Maine’s Stance 
 
Under Maine’s Labor, Commerce, Research and Economic Development distributed by 
direction of the Secretary of the Senate the state of Maine Senate 126th Legislature First Regular 
Session implemented “An Act To Facilitate the Personal Importations of Prescription Drugs 
from International Mail Order Prescription Pharmacies” (Maine.gov, 2014); in short, this is 
Maine’s, reimportation policy. The first in the nation to allow its citizens to import prescription 
drugs from foreign markets.   
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Many are inclined to assume that the drugs are coming in from Canada (solely) but this 
legislature allows for imports from Northern Ireland, United Kingdom of Great Britain,  New 
Zealand , and The Commonwealth of Australia that meet that country’s regulatory and statutory 
requirements (Maine.gov, 2014). Maine has stepped into the forefront as it battles the increase 
cost of prescription medications. Along with this new policy other programs have been 
implemented to aid the cause. “Health Maine Prescriptions” utilizes the purchasing power of 
Medicaid to give up to 25% discount to lower income individuals (Toner, 2002); Maine is 
ground zero but this is a national issue.  Surprisingly there are advocates on both sides of the 




  Basskin (1998) suggested one should consider asking several questions to get to 
the root of the cause of non-adherence. For example, is the reason for nonadherence preventable 
or avoidable?  Does improving compliance improve outcomes? To what degree does a specific 
intervention improve adherence and is the intervention cost effective? Patients have an ongoing 
responsibility to seek help and to confide with their physician/providers to help quail this 
problem. 
 The additional consequences of nonadherence with prescription drugs are documented by 
many studies. Frost & Sullivan (2006) has indicated that in the United States patients’ 
compliance with long term pharmaceuticals medication has an average of only 50 percent; 
estimation of nonadherence to pharmaceutical medication causes nearly 125,000 deaths per year. 
Also, according to Frost & Sullivan (2006), approximately 10% of hospital admissions and an 
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estimated 23% of patients in a nursing-home are due to drug nonadherence. Some one-third of all 
drug prescriptions are never filled, and more than (50%) of prescriptions that are filled are 
incorrectly administered. 
 The results of poor adherence are seen as the burden of chronic illnesses increases 
worldwide.  The outcome of poor adherence to long-term treatments results in poor health 
outcomes while increasing the cost.  Improving adherence also enhances the safety of the 
consumer. Effectiveness of adherence could possibly have increase implications health- 
conditions of the population than any other medical treatment; as a nation, health systems must 
step up to the occasion (WHO.org, 2003). 
Compliance vs. Adherence 
 
The new preferred term is adherence although often interchangeable with compliance a 
more definitive reference has been established for the terms. Compliance (original term) implied 
that patients following doctors orders. Adherence (appearing later in literature) refers to active 
patient participation and a doctor-patient partnership (Karmel, 2005) - this term allows for 
patients to assume more responsibility for their care. 
Adherence Measurements 
 
 Throughout many years non-adherence of 25% or greater have been monitored and 
measured through patient self-reporting, reports of prescription refilling, electronic monitoring, 
and with open-ended questions to patients (hoping for truthful responses). The World Health 
Organization (WHO, 2003) suggested one measurement approach is to ask providers on 
adherence behaviors, but there seems to be a tendency to overestimate their adherence. Simply 
counting remaining tablets can be performed at the clinic however inaccurate counting is very 
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common.  The WHO states that there are no definitive ways to assess specific behaviors that are 
reliable to predict adherence. 
Patients Who Fill and Not Filling Prescriptions 
 
 Several studies suggest that senior citizens are having the most trouble with adherence of 
their medication regimen. A study performed by Shah, Desai, Gajjar and Shah (2013) of 200 
geriatric patients (of various outpatient departments) suggested lower socioeconomic status, 
complex drug regimens along with the duration of the treatment significantly contribute to senior 
citizen’s nonadherence conduct. The research also stated the lack of education is a huge 
contribution factor; a United Kingdom study also reflected the importance of education 
intervention. Nordqvist (2011) noted an increase in drug cost has taken place along with a 
population increasing in age that has lead to significant financial burden to those needing 
medication. 
 Combined with high employment and increase insurance payouts by employees, coupled 
with many non-insurers many Americans under the age of 65 find themselves in the same 
predicament. 
Medicare Part D 
  The Medicare Prescription Drug Improvement and Modernization Act 2003 (MMA) 
represented a greater expansion of benefits to over 42 million senior citizens.  Activated in 2006, 
the program gave access to prescription drug benefit (Part D). The program gave rise for the 
need of improved drug coverage and opportunities to mitigate increase drug costs. 
 Five key elements for Medicare were realized in recent years, information obtained from 
a 2003 national survey conducted by Saran, Neuman, Schoen, Kitchman, Wilson, Cooper, 
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Chang, and Rogers resulted in the importance of prescription medicine in the healthcare system 
of the United States and the effects it has on elderly citizens. Secondly, the United States has 
over 40 percent of low-income citizens who lack insurance in several states. Third, Medicaid has 
had a positive role and moving patients over to the new Part D plans is essential; forth we see 
that not all plans are equal and that variances exists from state to state that requires extensive 
education, outreach and enrollment strategies (Saran et al., 2003). 
  Finally, the increased rates of nonadherence to prescription medications due to costs and 
other factors indicates that the new Part D plan may be of benefit in this matter in limited form 
but other nonadherence factors may need to be addressed via doctor/patient interactions and on a 
larger scale within the healthcare system (Saran et al., 2003). In a Consumer Report’s survey 
(2012), 62% (<65 y/o) declined medical test due to cost, 45% skipped filling a prescription due 
to high cost, 63% put off doctor’s appointments and 51% skipped a medical procedure; over 81% 
of the individuals said they had done at least one of these steps due to financial burdens (Morran, 
2012). One finding from the survey was that many consumers did not confide with professionals 
who could aid them. For example, the physician could have provided sample medication or 
offered coupon incentives from the drug manufacturer. Medicare is the largest purchaser of drugs 
in the world’s largest market.  By law, Medicare is prohibited to locate better prices. Getting 
Medicare to seek more affordable pricing would save the federal government $137 billion over a 
ten year period, according to the Congressional Budget office (journalinquirer.com, 2013). 
Preventive Healthcare 
 
 Public health and preventive medicine is guided by preventing diseases, promoting 
health, and managing the health of the community and populations. Health officials combine 
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public health skills, population, and knowledge of primary, secondary, and tertiary prevention-
oriented clinical practices in various settings (theabpm.org, 2014). Increase patient  drug 
adherence can provide a better outcome that can better reduce the chronic aspect of a disease; 
decreasing the more serious characteristics of long-term diseases; thus, overall healthcare savings 
would be seen having a better outcome for the patient (theabpm.org, 2014). 
 Another factor is patient/provider partnership-the extent in that patients and providers 
agree, adherence requires the patient to believe there is a beneficial component to taking 
medication; there cannot be any barriers and open communication is important, this comes only 
with time (AmericanCollegeofPrevention.org, 2014). 
Pharmaceutical Drug Cost Determinants 
 Determinants of drug cost from originator branded drugs across various regulatory setting 
and health care systems differ in many ways. For example, release date of the drug can play a 
significant role in pricing along with patent status and marketing techniques (Kanavos, 
Vandoros, 2011).  Distribution margins for generics and new medication hitting the market 
contribute to price formation throughout the country as well.   
 Kanavos, Vandoros (2011) stated exchange rates of countries and the volatility of the 
market can make a grave difference on pricing. But in the United States one must not forget 
about taxes and logistical factors that inflate pricing. Prices of branded medication do not 
necessarily decrease because of exhausted patents and the release of generic drugs.  
Reasons for High Cost 
 Many reasons can account for high drug cost in the United States; it is heavily 
documented that the pharmaceutical industry is allowed to set their prices (no government price 
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regulations). Zall (2001) noted Pharmaceutical companies intend to recover their entire costs and 
produce a profit. In order to recoup all the costs associated with research and development along 
with marketing, pharmaceutical companies will charge what the market can bear; that market is 
the consumers they serve. For example, mass advertising is fairly new, the process seems to be 
designed to appeal directly to consumers.  The nation’s pharmaceutical companies spent $1.3 
billion in previous years and recouped the cost in sales (Lancaster New Era, 1999).  The 
Lancaster Business Group on Health stated that increases in insurance premium along with 
increase co-pays contribute to this issue as well; most companies saw a 12-20 percent increase 
that will continue to rise. 
Swatz (1995) stated that the very high cost of research and development that exceeds 
$350 million per drug is why companies insist on 20 years patent protection, this helps drug 
companies to hold on to the drug and recoup costs. Kana, Ferrario, Vandoros & Anderson (2013) 
suggested that US per capita pharmaceutical spending has a rapid uptake of newer and pricier 
drugs in the United States in comparison to other countries. Simply put other countries require 
drug companies to provide strict evidence of the value of the new drug, the United States does 
not. Paul, Chandra & Lambrinos (2006) suggested that insurance has made drugs more 
affordable thus, increased the consumption and cost of pharmaceutical drugs. 
Long-term Healthcare Cost 
 Lueck (2002) wrote that Americans could have saved $38 billion in 2001 if Americans 
were allowed to make prescription drug purchases from Canada. Quon, Firszt, & Eisenberg 
(2005) performed a comparison of 44 brand drugs to the Canadian markets and concluded that 
Americans can save a mean of 24% if drugs were purchased from Canadian internet pharmacies; 
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stating that brand drugs are substantially less expensive. Savings is a two-fold concept in that 
direct purchases contribute significantly to healthcare savings and the affordability would lead to 
an adherence factor that would increase better living conditions and decrease the chance of 
diseases elevating to a worst state. 
 If one was to consider nonadherence alone, Frost & Sullivan (2006) suggested that 
nonadherence contributes to $100 billion (direct cost) to the United States’ health care system. 
Indirectly costs exceed $1.5 billion yearly due to the lost of patients’ earnings and unrecoverable 
productivity ($50 billion). The nature of this issue has prompted the National Council on Patient 
Information and Education (NCPIE) to term nonadherence as "America's other drug problem".  
Adherence Comparison; Canada vs. USA 
 Although the emphasis is on drug prices in the United States, we see problems in other 
nations having similar healthcare issues to tackle. In the United States and Canada patients 
having trouble funding their medication drugs are more likely not to adhere thus, risking increase 
illnesses and death while increasing healthcare cost (Kennedy & Morgan, 2006). 
   Kennedy & Morgan, (2006) indicated in a joint Canada and United States survey (2002-
2003) by the Statistics Canada (Ottawa, Ontario, Canada) and The U.S. National Center for 
Health Statistics (Hyattsville, Maryland) consisting of 3,505 citizens in Canada and 5,183 in the 
United States reported that residents of Canada are less likely to report cost-associated 
nonadherence (5.1% vs. 9.9; P< 0.001). The report goes on to say that Americans having no 
insurance (28.2%) and Americans & Canadians with no prescription coverage (16.2%) were 
more likely to report cost-related nonadherence. The conclusion of the survey stated the general r 
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cost-associated nonadherence is greatly higher in the USA (even with the availability of health 
insurance and pharmaceutical coverage (Kennedy, Morgan, 2006). 
Drug Tiers 
 Regardless of the paying entity such as private insurance company, Medicare, Tricare, 
Medicaid and other programs they all maintain a list of pharmaceutical drugs that they will pay 
out known as formulary. Formularies are comprised of prescription drugs, generic drugs, and 
often times over-the-counter medication (OTC) that were prescribed. It (formulary) is structured 
in such that they vary in co-payments. Torrey (2014) gave a summation of Tiers 1, 2, 3 & 4: 
Tier 1 or (I): Drugs are limited to generic brands- they are the lowest price drugs. Many lower 
prices branded drugs fall into this tier. Tier I drugs co-pays range from $10 to $25.  
Tier 2 or (II): This tier usually consists of branded name drugs and/or more expensive generics. 
Tier II drugs have value co-pay, ranging from$15 to $50.  
Tier 3 or (III): For more expensive brand name drugs, (most often not the first choice for your 
insurance company because of increase cost) they are also known as non-preferred. Tier III drugs 
cost are more than the lower tiers, having a range of $25 to $75 co-pay.  
Tier 4 or (IV): Known as specialty drugs: newly approved pharmaceutical drugs, and are so 
expensive that insurance companies will discourage patients from obtaining these prescriptions 
drug. Tier IV is a newer designation, initiated in 2009; tier IV designation seems to categorize all 
other expensive drugs. Co-pays are assigned a percentage and not a dollar amount.  
 Motheral & Fairman (2001) suggested that the three-tier drug co-pays can control cost 




Generic Drug Benefits 
 Many costs saving measures have been attempted to ease the cost of drugs. Physicians 
often give out sample drugs to individuals who are having trouble paying for their prescriptions. 
Pharmaceutical companies have initiated programs to assist consumers who by high cost are 
burden.  The government has even stepped in to promote generic drug production while 
decreasing the time to get generic drugs to market. 
  The Hatch-Waxman Act also known as the Drug Price Competition and Patent Term 
Restoration Act of 1984 is the most enhance drug-related legislation linked to the pharmaceutical 
and healthcare industries since the early 1960’s.  This act made it faster and easier to bring 
generic prescription drugs to market by mandating the FDA to only look at bioavailability 
studies in order to approve the drug known as the Abbreviated New Drug Application (ANDA). 
ANDA allows a 30-month cooling off period for challenges of patent infringements (NAPSRx, 
2013). This measure helped encouraged the increase of generic drugs over branded drugs, faster 
development, along with quicker delivery to consumers.  
 Dr. Emanuel (2012) stated that the cost savings can be achieved by substitution (using) 
generic drugs. During the years of 2004 to 2009, the use of generic drugs for branded drugs 
increased to 75% from previously 57%. In 2010, the United States spent an estimated $262 
billion of prescription drugs equating to approximately 10% of total healthcare expense $2.6 
trillion (WHO.org, 2014). 
Contrasting Markets Using the European Pharmaceutical Industry 
 For every aspect of this issue (reimportation) the United States should look 
beyond its borders and be willing to adopt portions of legislation (from other nations) that 
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eliminate unproductive outcomes and promote better quality of life; this is in alignment with the 
theoretical framework of Lewin’s organizations change theory that this research has adopted. 
Contrasting this market is important for United States’ officials to see that an existing 
reimportation model does exist. The European program also reassures the public that no 
pandemic or epidemic is occurring as it relates to reimportation of drugs (known as parallel 
imports in Europe) lending a sense of security and safety to the masses. 
It is significant to note the tremendous savings has been afforded to the European 
healthcare system.  Replication of this process is possible in the United States with slight 
modifications that suites the demographics population and the U.S. healthcare structure.  In other 
words, there is no need to develop a process from infantile stages when a fairly workable model 
exists. It is important to observe the components of their (Europe’s) structure, pricing policies, 
and price control strategies. 
 In the past two decades or so expenditures on pharmaceutical drugs and other healthcare 
costs have increased faster than gross national product of all European nations (Ganslandt & 
Maskus 2004). European policies are multidimensional and accounts for issues of public 
expenditure, public health, and pharmaceutical incentives.  Consumption patterns and various 
pricing levels determine the   total expenditure that varies across the various European nations. 
 Ganslandt & Maskus (2004), stated pricing policies are generated by product price 
control, reference pricing and profit controls. Product pricing control is use in determining the 
prices of medication. The vast difference was the introduction of Single European 
Pharmaceutical Market that implemented parallel imports (Ganslandt & Maskus 2004). Similar 
to the U.S. market several practices have been put into place to control cost of patients’ expense.  
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The uses of generic drugs are encouraged, also providing a listing of drugs that are reimbursable 
(positive list) or a negative list (one that does not reimburse) including the co-payments of each 
drug. 
Due to the Single European Market structure it is not surprising to know that countries 
reimport drugs from each other all the time. Using data from a Sweden research, prices from 
parallel imports decreased in comparison to other drugs over the time period of 1994-1999 
suggesting parallel imports (reimportation) decreasing manufactured cost by 12-19% indicating a 
saving can be passed on to patients (Journal of Health Economics, 2004). 
Political Aspect-Congress 
 Klein (2014) suggested that many people feel the Affordable Care Act (Obamacare) may 
hold the pharmaceutical industry more in line, give the government some leverage of drug 
pricing, and allow for reimportation of drugs from Canada.  Congress has spoken out on many 
occasions; with rhetoric from both aisles the 113th Congress talked about Medicare cuts. They 
suggested that billions of dollars could be saved over the next decade if new policies were 
implemented.  They suggested putting Medicare drug out for bidding, allowing reimportation of 
safe drugs and banning “pay for delay” of generic drugs. 
 The Preserve Access to Affordable Generics Act of 2013-2014 would end brand name 
pharmaceutical companies from keeping equivalent generic brands off the market pay for delay.  
Yates (2013) suggested reintroduction of Senate Bill-319 (S-319 of the 112th Congress); 
sponsored by Senator Snowe (Republican-Maine).The bill will revise provisions governing the 
reimportation of prescription drugs (Congress.gov, 2014).  Several senators from northern states 
are pushing for new policies; the lawmaker’s bill gives permission for U.S. pharmacies and 
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wholesalers to resell and buy medication from Canada.  Proximity to Canada seems to be one 
indicator for these northern states pushing for new legislation. 
Federalism 
Implementation of such federal policies will require dialog from both state and federal 
officials. Federalism in the United States evolves relationships between state and federal 
governments of the United States; the American government has evolved from a dual federalism 
system to one of associative federalism (Cornelllaw.edu, 2014). This arrangement has various 
agents, departments, and trustees of the people constituted with various levels of power. It is a 
political concept that has a group of members bounded together by a covenant.  The term is 
frequently referred to as a level of sovereignty. 
 In order to improve the plight of patients and improve patient adherence no one single 
component will do. When coupled with other programs and policies, reimportation could aid the 
situation and allow researchers, physician (and others) to address patient adherence.  But first, 
there must be a new order of federalism (a system of government in which the same territory is 
controlled by two levels of government Cornelllaw.edu, 2014) that will conform to both state and 
federal levels of government that will give more sovereignty without repercussions.  This 
increase power of freedom would allow state levels to take the bold, rogue steps to improve 
healthcare accessibility to drugs as seen in Maine.  
 Better quality of life has always been the agenda and consideration in pharmaceutical 
development. It is quite difficult to see the effects if patients are non-adherent. Dr. Kweder 
(retired deputy director of the FDA) stated medication can’t work unless it is taken (FDA.gov, 
2014). The largest world markets of pharmaceuticals (United States, Western Europe, Japan-
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respectfully) all suffer from a market-place that lacks standardization; this fact contributes to the 
complexity of the pharmaceutical enterprise. 
 As the leader of the world in many aspects, the United States should take the lead at 
standardization, development and affordability; thereby new policies are needed. Converting to a 
pharmaceutical structure seen in Europe may have many benefits; the parallel import 
reimportation structure has worked for over two decades.  
Summary 
 Literature on non-compliance of patients having various chronic diseases has revealed 
that the cost is a common theme.  Although other factors come to light, several research studies 
and surveys have concluded that the cost related non-adherence is a major concern.  
  The literature review also demonstrated that many voices exist on the topic of 
reimportation of pharmaceutical drugs. Research variables “reimportation” and “patient 
adherence” is null within the literature review. Because of the opportunity occurring in Maine, 
these variables can now be addressed. An important component to this exploration while 
underlining a fluid, adaptive approach is the theoretical framework. Lewin’s (1947) theory of 
organizational change is a solid approach to what is needed for reimportation adaptation. A 
smooth, transient mindset change can be achieved with Lewin’s organizational change; with 
emphasis on unfreezing, change, and the freezing approach. This approach allows for releasing 
insufficient processes, making a change to a more sufficient process (or policies) and then 
locking those new changes into place.  
 Millions of low-income individuals and senior citizens (with fixed income) cannot afford 
the high price of their drugs as evidenced by a 2013 Commonwealth Fund study that stated 50 
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million Americans did not fill a prescription due to high costs in 2012 (Hamburg, 2014). Thus, 
patient non-adherence will continue until a series of resolutions are identified and executed.  
 Contributing to this research was a qualitative, grounded theory approach. This 
methodology aimed to get a better understanding through field experiences, truthful data 
collection, along with accurate conversation feedback (validation-member checking process). It 
strived to comprehend how the informants derive meaning from their experiences, and how these 
experiences influence their behavior (Creswell, 2007). Chapter 3 outlined how this research was 

















Chapter 3: Methodology 
Introduction 
 After a review of the literature this study focused on two variables: reimportation of 
pharmaceutical drugs and cost-related non-adherence (CRA). Several factors contribute to non-
adherence of patients’ drug regimen, but cost is relevant to many senior citizens and individuals 
with chronic diseases. Briesacher, Soumerai &Gurwitz (2007) suggested that many links exist 
between prescription drug nonadherence because of the high cost and social economics, but due 
to depression and other diseases. The literature is null as it relates to reimportation of drugs and 
increasing patients’ adherence for patients with a chronic disease. Kurlander, Kerr, Krein, 
Heisler & Piette (2009) stated that patients who do not comply with their medications for chronic 
pain seem to stem from pressures of their economic status, where other patients who selectively 
reduce their regimens are driven by their own perceptions, personal beliefs, and moods. 
 A better understanding of reimportation and adherence is required to improve the plight 
of patients with chronic diseases. Therefore, it is important to obtain data from a population 
(within the United States) who can legally obtain prescription drugs without clandestine efforts. 
Qualitative method and grounded theory were selected for this research in order to determine the 
effectiveness of the reimportation policy. The chapter described the rationale for utilizing 
grounded theory, qualitative paradigms, complete description of the design, the sample 
demographics (population), descriptive of the data collection methods, grounded theory protocol 





          Research Design and Rationale 
 Reimportation drugs are developed, produced and bottled in the same exact facilities as 
domestic drugs, with the exact same labeling. Many people find it quite difficult that the Food 
and Drug Administration (FDA) cannot create logistic safeguards to ensure that this process 
could be undertaken in the United States. Dayen (2009) suspects a more sinister reason as he 
suggested that any reimportation implementation would void the pharmaceutical industry’s 
backroom deal with Senate Finance Committee Chair (Max Baucus) and the White House, which 
limited the drug industry’s exposure to “losses”. This deal was set at $80 billion dollars over a 
ten-year lifespan. Therefore, we have cost-related nonadherence due to the pharmaceutical 
industry’s proclivity towards profits. 
  I selected the grounded theory approach to determine the effectiveness of the 
reimportation policy within the study population (Maine) and to gain knowledge of the 
perception of this policy on said population. The grounded theory design and qualitative method 
are appropriate as suggested by its paradigm of advocacy and participatory characteristics. 
Creswell (2008) suggested that this worldview “needs to be intertwined with politics and a 
political agenda” (p.9) thereby having an action agenda for reform. 
Role of the Researcher 
 Rudestam & Newton (2001) noted that data gathered from qualitative research is 
compiled from various tools: questionnaires, interviews, personal knowledge, audio recordings 
and documents of previous scholars. Researchers then proceed to review the data obtained from 
these many sources; throughout the process categories (primary) and additional categories are 
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generated, and the creation of theories are introduced. Creswell (2007) states that assumptions, 
worldviews, bias about the study and the participant pool should be established initially. 
 Creswell (2008) noted that qualitative researchers play the primary role as a tool in data 
collection they embark personal values, biases and assumptions prior to the study. In this 
research project, data was recorded from open-ended and close-ended interviews and 
questionnaires with participants. This form of recording was provided via electronic digital 
recording and note taking. I developed and designed the questionnaire/interview questions to 
address the following research questions: 
 RQ1: How does a reimportation of prescription drug policy contribute to    patients’ drug 
 adherence? 
 RQ2: What perceptions do patients have about reimportation drugs as related to  a 
 chronic disease? 
 RQ3: What are the perceptions of key providers (physicians, physician assistants & nurse 
 practitioners) regarding the impact of reimportation drug laws on patient medication 
 adherents? 
Pilot Study 
 A feasibility study (pilot study) was performed to determine the appropriateness of the 
interview questions in order to yield a refinement component for better understanding and foster 
responses that are necessary to answer the research questions. This study took place one day 
prior to the actual research start date.  The participants in this study yielded data that was not 
utilized in the data analysis process. Conducting this feasibility study does not necessarily 
guarantee success within this exploration, but could increase the likelihood of success. It is the 
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desire of this feasibility study to fulfill a series of important functions that can yield valuable 
insight for the primary exploration. 
Bias Interpretations 
 Bias in qualitative research is a problematic concept, because qualitative researchers are 
part of the process, and researchers vary in style and approach. The human element has been 
stated to be the greatest weakness and the greatest strength of a qualitative method. Qualitative 
research mandates explicit acknowledgement of bias, in contrast quantitative attempts to 
eliminate bias completely. This research has bias components as well and must be declared.  This 
declaration is noted due to the confinement of all the fieldwork to one geographic location, 
suggesting that other major markets are not represented. The uniqueness of this study requires a 
sampling population of one locale (the state of Maine). This state is the only locale that can 
provide the participant pool needed to execute said study because of new state policies for 
reimportation. All participants were pooled from this region.  
 The research also notes bias within the educational and socioeconomic realm. The study 
does not make any assertions of patients’ level of education on reimportation, pharmaceutical 
drugs, and non-adherence levels. Thus, higher educated participants with knowledge of 
reimportation, the pharmaceutical industry, and patients’ non-adherence could be excluded from 
the study.  Also, since a major component of the research is related to cost-related issues, one can 
assume that socioeconomic factors play a significant role of the participants. Therefore, the more 
affluent population may not be represented adequately in this study; income levels of these 





 The research project has conformed to all mandated requirements of Walden University 
and Walden Institutional Review Board (IRB).  I (as a researcher) “respected the rights, values, 
needs, and desires of the informants” (Creswell, 2008, p.198). Articulation of the identity of the 
study, the role of the research, and risks (if any) was given to all informants. Informants were 
informed that all data collected will be kept in confidence and that they would not be identified 
by first or last name.  The informants were informed that their responses will only be seen and 
reviewed by the researcher. 
 Informants were briefed on the importance of their rights to refuse to participate and that 
they are under no distress or pressure to participate.  Articulation to participants (patients) stated 
that a small monetary (gift card) was being offered for their participation efforts by the 
researcher.  No incentives were negotiated with any institution. It was articulated that 
participating in this research is strictly volunteer.  Written permission from informants to proceed 
with the study was received and documented.  For those who choose to participate, they were 
told at any time they could exit the project and it was solely their right to do so without any 
repercussions. For any individuals (on site) who volunteered and assist in any manner, it was 
articulated that protecting the informant’s data is of priority in this research study and a sign 
confidentiality agreement was required. For any follow-up concerns (i.e. validation, credibility) 
informants were handed a participation identification number in such that their questionnaire and 





Sample and Setting 
 Sampling (in general) is a complex topic. Determining the appropriate number of subject 
is one complexing aspect of sampling. Creswell (2007) states that an adequate number range for 
a qualitative method consists of 10-30 informants; cost and time are important factors when 
considering sample size.  The sample size in this research (20 participants) is needed to develop 
a well-saturated theory and is suitable for smaller participant pools (Charmaz, 2006). The 
theoretical saturation consist of qualitative data analysis that have continued sampling and 
analyzing of data to the point that no new data is identified and other concepts in the theory are 
well identified and developed (Morse, 2007). Concepts and linkages have formed a theory and 
verification (member checking) have been performed. This inductive analytical approach 
concludes that no aspects of the theory remain hypothetical. Morse (2007) goes on to state that 
all conceptual boundaries are marked. Allied concepts have surfaced, documented, and 
delineated. Theoretical saturation is the belief of theoretical sensitivity; this assumption of 
theoretical sensitivity is that data analysis is driven by the data collected. 
 The research atmosphere and settings are important components as they set the tone of 
the research.  For example, this research conducted research interviews on location in the state of 
Maine; the logic behind this was that (participants) would feel the research is for official 
business and provides a sense of comfort. 
 Informants were selected based on their ability to contribute to this research while 
seeking a threshold of saturation (Creswell, 2007). This research reached out to a sector within 
the state of Maine that uses reimportation drugs and who are familiar with this policy.  This 
study attempted to use the various sectors of the city of Portland, Maine for patients and the 
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entire state for providers.  Healthcare providers were selected via social media and they provided 
their inputs. Patients were selected based on their interest from a poster.  Also, patients were 
approached and solicited (fact-to-face) for their help to this research. 
 When utilizing these providers it was the desire to encompass certain characteristics of 
the providers.  Since the interview questions have been designed specifically for the providers 
and patients, it was important to have a manageable working relationship with the patients (from 
the view point of the providers).  Although the providers make up 50% of the participant pool 
they have access (and will give their perceptions) to several patients; thereby rendering valuable 
information (indirectly) about patients’ plight. In order for them to share this information, they 
should process the ability to listen well resulting in a nonjudgmental approach. Strong doctor-
patient relationship was needed for the sake of trust, respect and partnerships are a desired trait 
as well. These characteristic components can influence the analytical process. 
 Patients and providers were called upon via email, social media and telephone 
conversations before traveling to various site locations in Maine. Once these individuals were 
identified it was necessary to invite them to the research study.  Providers responded 100% via 
email and social media. I formulated an email containing the research information and attached a 
consent form and questionnaire and sent out to providers who met the criteria. The identity of the 
study along with their rights was also articulated. Those accepting this opportunity signed and 
returned the consent forms. Charmaz (2006) suggested that the focus of the research is the 
ultimate driver of the project design, and the size of sample population. It is suggested that a 
smaller studies with modest claims can achieve saturation sooner verses a study that is focused 




 A qualitative research study using grounded theory as the design was selected for this 
project due to (a) literature review yielded deficits in data for reimportation and the effects on 
patients’ adherence, and (b) grounded theory affords researchers the opportunity to compile a 
theory (Creswell, 2008).  In contrast to quantitative who employ experimental/quasi-
experimental design that often controls the outcome of the research while restricting the focus of 
attention (Rudestam & Newton, 2001). Patton (2002) suggested that quantitative methods have 
the possibility of not capturing the total dynamics of the responses from the participants or how 
the project affects the participants. According to Buckley & Waring (2009), researchers benefit 
from the qualitative approach because it allows nuances of languages and behaviors to be 
detected that can contribute to a qualitative approach often select nonrandom sampling that 
yields inferences from the research as it relates to the whole population (Creswell, 2008). This 
research study benefited from the use of convenience sampling, making a qualitative approach 
more appropriate. (Rudestam & Newton, 2001) stated that there is no national standard approach 
within social sciences “although a common understanding that chosen methods of inquiry must 
rest on rational justification” (p.23). Patton (2002) observed that qualitative methods (grounded 
theory) often produce significant details about smaller number of participants therefore, I 
rejected ethnographic method because it required a large culture group setting that requires 
researchers interpretations. 
  Case study was not a proper fit due to the limited number of participant’s need to 
describe their experiences at a specific time (Creswell, 2008) and because of the individual 
responses desired. I looked at the perceptions of this population with efforts concentrated on 
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several participants at various junctures thus the narrative approach was not selected due to the 
writing experiences of a single individual and the creation of a narrative story line that described 
those events. The various past experiences and different backgrounds that are sought in this 
study requires an individuality approach; the interpretations of the phenomenological approach 
would not be appropriate as “shared beliefs” (Creswell, 2008) of the participants is the focus-
therefore rejected. 
 Qualitative approach was designed and developed in 1967 by researchers B. Glaser and 
A. Strauss (sociologist) who beliefs consist that theories should be “grounded” and have a 
genesis in the field. This method required a theory of interactions, and actions based on data 
collected from the participants (Creswell, 2007). They also stated a revision to constructivist 
grounded theory in which individuals construct both the phenomenon and the research process 
through actions.  More recent theorist advocated constructivist grounded theory thereby 
introducing another perspective onto grounded theory procedures. Patton (2002) noted that a 
constructivist looks at how variables are grounded, given meaning and how it plays out in 
participant lives.  Constructivist grounded theory gained support with its introduction by K. 
Charmaz in (2006); yet other viewpoints were supported by A. Clark (2005). She (Clark) relied 
on postmodern perspectives such as the political nature of research and the interpretation 
(Creswell, 2007). 
 Grounded theory has several defining features that may be incorporated into a research 
project; the researcher must focus on processes that have guided steps overtime thus, grounded 
theory has movement. Researchers also seek (in the end) to conclude with a theory that may 
come in many forms. But, in simple terms it (theory) defines the understanding of the data that 
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was collected. Memoing is integrated as it allows researchers to write down ideas as the data is 
collected and analyzed; this form of data collection is often in the form of interviewing, 
questionnaires, focus groups and recorded memos (Patton, 2002). Lastly, data analysis is 
performed to developed categories that aid the theory process while detailing additional 
categories in which incorporates inductive style approach (Creswell, 2007). Using inductive 
approach for analysis (a) processes raw textual data into a succinct summary format; (b) 
develops clear and concise conceptual links between the evaluation and the summation drawn 
that is concluded from the raw data; (c) develops a structure of the underlying framework of 
experiences (Thomas, 2006). 
Research Design 
 According to Denzin and Lincoln (1994), a qualitative study needs the interpretation of a 
phenomenon within their natural habitats in order to make sense of the meanings informants 
bring to the research. Qualitative research involves memoing, collecting information, sorting, 
note taking, and data collection and coding about personal experiences of the informants; this is 
acquired by interviews, interactions, historical, and visual text which are pivotal moments that 
have a meaningful component in people’s lives.  
 Patton (2002) defined qualitative research as making an attempt to comprehend various 
interactions in a situation. While purpose of comprehending is not to predict what may or may 
not occur, yet rather to make every attempt to comprehend in depth the components of a situation 
and the meaning that participants contribute during that moment. Qualitative research is the most 
flexible techniques, it uses a variety of methods and structures that are accepted throughout the 
research arena; from individual case study to very in depth interviews, these types of studies 
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demand carefully constructed and planned designs.  No standard structures have been adopted; 
interviews, case studies, and survey designs are the most often used methods.  
 According to Rudestam & Newton (2001), qualitative design has 10 considerations that 
researchers should realize; (a) the focus of the inquiry, (b) determine the worldview (paradigm) 
to focus, (c) determine the fit of paradigm to the substantive theory, (d) one must decide on 
where and from all data will be collected, (e) is there a need for additional phases of the inquiry, 
(f) what instrument(s) will be used, (g) data collection and recording codes, (h) data analysis 
process, (i) planning the logistics, and finally (j) plan for the validity process. 
 Several advantages are seen with qualitative techniques. Qualitative is quite useful when 
subjects are too complex, and no simple yes or no hypothesis can be discerned. They 
(qualitative) designs are easier to plan and execute. Many feel they are useful when financial 
decisions have to be considered. Within a broader view qualitative designs often succeed in 
generating useful information in contrast to quantitative; it (quantitative) can generate an 
unproved hypothesis resulting in valuable time and resources being wasted (Shuttleworth, 2008). 
There exist smaller sample groups with qualitative because it is not necessary to rely upon 
sample sizes with qualitative. 
 Qualitative is not perfect; researchers must realize at very early stages that a lot of careful 
thought planning is required (Shuttleworth, 2008).  One disadvantage of qualitative is that data 
cannot be statically (mathematically) analyzed in the same comprehensive manner as 
quantitative; thereby only a general pattern is seen. Qualitative is design for various 
interpretations due to the open, opinion and judgmental components and duplications are more 




 All informants were coded with a participation identification number. Demographic 
profile obtained consisted of: age, race, gender, smoking status, and chronic diseases. All 
information from patients was collected at the study site in Maine with the exception of one 
patient. The identity of the study was articulated, and the rights of the patients and providers 
were given. For example, participation in the research is strictly voluntary and early withdrawal 
is an option to the participants.  All questions at this juncture were addressed. Moving forward, 
individual interviews were performed. I utilized random sampling; this method increased the 
credibility of this study. I located healthcare providers in the state of Maine that met the criteria 
of the research.  Providers were located via “Linkedin.com” a profession social media website.  
The site allowed for identification of occupation, location, and other pertinent information that 
was needed for selection.  Upon reaching out to these professions and befriending them, I was 
able to send them (directly via their personal email address) a detailed email explaining the 
research.  I also, attached the consent form and the questionnaire to the email.  This method 
allowed for the research to reach various healthcare professionals throughout the entire state of 
Maine thus, a better representation of healthcare professions were obtained. Those who elected 
to participate signed and returned the consent form and questionnaire. 
 The individual interviews for patients were selected instead of a case study (group) 
because I wanted individuality. For example, I did not desire a response from PT3 to be based on 
what he or she heard from PT7. Interviews consisted of open and close-ended questions 
developed by the researcher; as suggested by Creswell (2008) a central question and sub-
questions was established. I initially engaged in dialog (ice breakers) in order to get the patients 
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comfortable with me in their environment. I welcomed all questions related to the research and 
my credentials. Engagement was be brief not to intrude on normal behavior patterns which could 
cause a decrease in honesty (Creswell, 2007). 
 According to Birks, Chapman, & Francis (2008) memoing allows researcher to make 
conceptual leaps of the raw data to those abstractions that gives explanation of the research 
within the context that is examined; therefore memoing is applicable to this research project. 
Electronic recordings of each interview was performed this aided the transcribing process. This 
research project benefited from face to face (FtF) interviews for several reasons. According to 
Opdenakker (2006) the interviewer and interviewee can directly have a reaction to what the other 
does or says. One advantage of this synchronous communication is that answers are more 
spontaneous from the interviewee. FtF can also aid this research due to social cues that are given 
off by the interviewee. This method yields the interviewer additional information that can be 
added to the study (Opdenakker, 2006). A combination of questions being read aloud and 
informant’s responses will comprise the interview process. 
 Upon completion of the interview process, analyzing and transcribing commenced.  This 
process was performed manually in order to formulate codes, categories, themes, and sub-
themes. 
Issues of Trustworthiness 
 Validity of this project will proceed with member checking by sharing the transcripts 
with the informants.  Goldblatt, Karnieli-Miller & Neumann (2011) noted that sharing research 
findings from a qualitative method with participants, member-checking is perceived as a process 
54 
 
formulated to increase research credibility and informant’s involvement. Throughout this process 
and post interview, informants were given the opportunity to clarify any inaccurate information. 
Data Analysis 
 Data from this research was coded manually and allowed the data to be converted into 
themes (Creswell, 2007). The research consisted of interview questions consisting of close-ended 
and open-ended format. Close-ended question consisted of age, gender, race, chronic disease 
status. These questions contributed to the demographic profile of informants. Also, close-ended 
questions within the interview questionnaire were formulated. These questions gave substantial 
support to the overall research project, whilst supporting the research questions. Open-ended 
questions allowed informants to explore and elaborate on their experiences pre-policy era and 
post policy era, in the hopes they will convey true personal perceptions, experiences and 
opinions. According to Throne (2000) data allows qualitative study to stand out with a category 
of principles, assumptions, values concerning truth, and real life; in contrast, quantitative 
research that uses the scientific methods to understand reality.  
 Data retrieved from this research project involved voice responses, informant’s reactions, 
tonations (voice projections) and developed ques to identify and capture non-verbal reactions.  
All interviews were held individuality. This design allowed the researcher to capture true 
responses from the informant and decrease the “copy cat” response heard from other informants 
(often) seen in group or case settings. Retrieved data was safeguarded according to Walden 
University (IRB) guidelines. Information was (and is) stored on my personal computer, personal 
cloud (virtual) account (which is password protected) and is safeguarded for future use for a 
number of years that is applicable to Walden University (IRB) policies. 
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 Creswell (2007) suggested that field notes, interviews be situated in some type of order 
for the purpose of analyzing. The purpose for this process is to develop core variables to aid the 
relationship amongst codes and concepts, generate themes and subthemes that will be used to 
generate a hypothesis. Coding was in three stages; open coding, axial coding and selective 
coding. Each coding has specific features; categories are formed with open coding, assembly of 
data in new ways is seen with axial coding, and linking the categories is seen for selective 
(Creswell, 2007). Persistence, an innovative data-gathering approach, and inquiring mind, can 
navigate a researcher into undiscovered worlds and provide rich data. The research made every 
attempt to do this. I validated this research with member checking via repeating informant’s 
statements back to them and allowing for any further corrections and clarifications in order to 
verify the accuracy. To further validate, I used opposing views and contrasting viewpoints to the 
themes that manifested. 
Several interview questions have been developed and designed to address the three research 
questions:  




 RQ2: What perceptions do patients have about reimportation drugs as related to a   
  
 chronic disease (diabetes)? 
 
 RQ3: What are the perceptions of key providers (physicians, physician assistants & nurse 





 Two sets of questions were developed and designed in response to the research questions. 
The first set is designed for the patients (informants) referred to as “Informant Questions” (I.Q.). 
The next set is designed for the providers (physicians, nurse practitioners, and physician’s 
assistants) referred to as “Providers Questions” (Pro-Q): see appendix. 
 
 The following (I.Q.) were used for research question-1 (RQ1); 1, 2, 3, 4, 5 (see 
Appendix I). 
 The following (I.Q.) were used for research question-2 (RQ2); 6, 7, 8, 9, 10 (see 
Appendix I). 
 The following (I.Q.) were used for research question-3 (RQ3); N/A (see Appendix I). 
 The following (PR-Q) were used for research question-1 (RQ1); N/A(see Appendix 
P). 
 The following (PR-Q) were used for research question-2 (RQ2); N/A (see Appendix 
P). 
 The following (PR-Q) were used for research question-3 (RQ3); 1, 2, 3, 4, 5 (see 
Appendix P). 
 
  At the conclusion of this research process, I disclosed data analysis to all appropriate 
parties and deliver hard copies including a copy to Walden University for publication into 
ProQuest Dissertations or any other forum within the university. 
      Summary 
          This chapter briefly discussed and outlined the design (grounded theory) and the 
methodology (qualitative) use for this research project. This approach and design method was 
chosen because of deficiencies in the literature review material and because of the flexibility it 
provides to informants for their opinions and feelings. Data collection was performed via 
questionnaires, and interviews. All questions posed to the participants consisted of open and 
close-ended questions; validation for accuracy was performed by member checking.          
Chapter 4 will consist of the research findings, the process in which these findings were acquired 
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and to analyze data that was discovered from the perspective of the informants in relationship to 























Chapter 4: Results 
Introduction 
 The purpose of this research was to investigate one component of patients’ non-
adherence of prescription drugs cost- related non-adherence (CRA) and research if reimportation 
of said drugs will have an effect on prescription drug adherence among the American population 
who have a chronic disease. Two theories were used to navigate this study; a grounded theory 
approach and Kurt Lewin’s organizational change theory.  Three research questions were 
devised from the theories: 
            RQ1:  How does a reimportation prescription drug policy contribute to patients’ drug 
 adherence? 
 RQ2:  What perceptions do patients have about reimportation drugs as related to a 
 chronic disease? 
 RQ3:  What are the perceptions of key providers (physicians, nurse practitioners, 
 physician assistants) regarding the impact of reimportation drug laws on patients’ 
 medication adherence? 
 To address these questions, 10 health care providers, and 10 patients were invited to 
participate in the research. Health care providers who prescribe drugs in the state of Maine 
consist of physicians, nurse practitioners and physician assistants; these 3 professions made up 
the health care providers for this research.  Patients consisted of individuals who have a chronic 
disease that warrant refill of prescribing medications.   Participants (patients) in the study were 
diagnosed with several diseases such as diabetes, cancer, thyroid disease, hypertension, high 
cholesterol and attention deficit disorder. They are currently taking medication for their 
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conditions.  In this chapter, the procedures utilized to ensure quality of the data will be discussed. 
The population sample of study and methods used to analyze the data will also be discussed.  In 
chapter five, the research findings will be summarized. 
Demographics 
 Upon receiving institutional review board approval from Walden University (Walden 
University Institutional Review Board (IRB) approval number # 04-22-15-0289886; I contacted 
several physicians, nurse practitioners, and physician’s assistants in the state of Maine. I also 
reached out to patients via the public forums (social media-Linkedin.com) and from face-to-face 
encounters upon arrival in Portland, Maine. 
 All participants were of adult age and met the criteria for the research that included: 
diagnosed with a chronic disease, monthly medication use, a citizen of the state of Maine, and 
knowledge of acquiring drugs from non-United States markets. The research yielded a majority 
of Caucasian ethnicity but also included other ethnicities; a right mixture of males and females 
were also involved. 
Protection of Participants 
 As the researcher, I approached this exploration with the responsibility of protecting the 
rights of all participants. This research had a focus to abide by the Health Insurance Portability 
and Accountability Act (HIPAA) thereby, maintaining complete confidentiality of all data that 
was collected.  The names of all participants were not disclosed. The only identifiers utilized 
were the conversion of names to patient and provider numbers (for example: PT1, PT2, PT 3… 
and PR1, PR2, PR3-for providers).  
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 This research consisted of two sets of population sampling (patients and health care 
providers).  Several challenges awaited this process (in relation) to recruitment of candidates 
from a great distance.  I had no previous contact information on participants therefore, I had to 
develop methods of communication and be creative in locating this specific population sample.  I 
decided to recruit providers first because of the strenuous work schedule I needed ample time to 
reach them and to acquire their participation; I turned to social media in this effort.   
 I crafted a brief, detailed statement explaining the research and attached the consent form 
and questionnaire to an email.  This email was sent to several health care professionals in the 
entire state of Maine. I befriended several individuals on social media website“LinkedIn.com”. 
The social media site provided detail information of individuals that allowed for selections that 
met the research criteria. For example one is able to see occupation, location, email address, and 
other pertinent details that allow for selection.  After their acceptance, I then sent the email 
containing consent form and questionnaire.  This method of recruitment allowed for multiple 
providers from various regions of Maine to participate, thereby lending an accurate 
representation of the health care population within this state.  All patients’ data collection was 
performed face-to-face in Portland, Maine. One exception was PT1 who submitted her answers 
via email. All informants participating in this research agreed to the terms of the research by 
signing the consent form and returning it with a completed questionnaire.  Data collection from 
participants (both patients and providers) was in the form of email submission, phone interview, 
and face-to-face interaction. 
Researcher as Instrument 
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 Researchers in qualitative methodology research are the primary instrument of the study 
(Hatch, 2002).  To maintain complete neutrality and increase credibility of the study, I scrutinize 
my attitude and biases initially prior to the study.  I also realized that different people have 
different perspectives, and I must adapt to the participant on an individual basis.  This adjustment 
was needed to maintain consistency within the questioning and follow up process (member 
checking). I anticipated various responses, gestures and behaviors and accepted answers as they 
were (with further clarification when needed). I expected to succeed in collecting the data within 
a particular timeline. And found that the citizens in Maine that I encountered (generally 
speaking) were very welcoming and eager to help in the name of research. 
Data Collection 
 The research study consisted of 20 participants n=10 (patients), n=10 (providers).  
Patients answered a 10 question interview/questionnaire survey and providers answered a 5 
question interview/questionnaire over a 12-week period.  Data collection took place from April 
23, 2015, to June 21, 2015.  Providers’ data collection commenced initially because of the 
various time constraints health care professionals have.  I wanted to allow additional time for 
them (if needed) and be flexible to their schedule.  Thus, sending the questionnaire via email was 
the most appropriate way that allowed for them to answer at their convenience while agreeing to 
a deadline. Extended time was given to obtain the 10 participants that were needed. Patients’ 
answers were obtained in Portland, Maine after articulation of the research and receiving signed 
consent agreements from all participants. Patients’ interview took approximately 10-12 minutes 
to complete, and additional time for follow-up questioning was needed to clarify answers and to 




 I developed 15 interview questions to address and answer three research questions. Ten 
questions focused on patients’ perceptions, and the remaining five were for the perceptions of the 
health care providers.  Interview questions PT1, PT2, PT3, PT4, and PT5 were formulated to 
answer Research Question 1: How does a reimportation prescription drug policy contribute to 
patients’ drug adherence? I utilized interview questions PT6, PT7, PT8, PT9, and PT10 to 
answer Research Question 2: What perceptions do patients have about reimportation drugs as 
related to a chronic disease? These two research questions had a focus on patients’ perceptions.  I 
used interview questions PR1, PR2, PR3, PR4, and PR5 to address Research question 3: What 
are the perceptions of key providers (physicians, nurse practitioners, and physician’s assistants) 
regarding the impact of re- importation drug laws on patients’ medication adherence? 
Transcription of data was completed after leaving the Portland, Maine research site.  All 
questions were developed as open-ended questions to foster more detailed answers from the 
participants.  
 Providers’ questions being sent out via e-mail (electronic mail) address afforded the 
opportunity for participants to take their time and address the questions without any external 
factors.  Thereby, they were able to perform a self-member checking before submitting their 
responses to me. But upon receiving answers, I thanked the participants for their help.  During 
this line of communication, I asked if any information should be added or changed (member 
checking).  One exception ensued with PT1 who submitted her answers via email. PT1 was 
afforded the same self-member checking as the providers and a follow-up email to her was sent 
for member checking as well. Upon receiving the answer, I found no ambiguity; all the answers 
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were clear and well understood. Although questions were open- ended and remained unchanged 
post-pilot study some responses were short and required further probing to understand further 
what the participant was attempting to say. The interview schedules for both providers and 
patients are listed in Tables 1 and 2. Provider’s schedules were developed based on the receipt of 
the answers via e-mail.  Assignment of identifiers numbers were randomly given (immediately) 
upon receipt of answers.  Patients’ identifiers were given immediately following their interview; 
PT1 was the only patient to respond via e-mail on May 22, 2015; all other patient surveys were 
performed face-to-face. 
Table 1- Schedule of Interviews/Questionnaires Surveys (Providers) 
Date        Providers (PR)      
  
5/1/2015    7 
5/2/2015    10 
5/2/2015    8 
5/3/2015    3 
5/4/2015    2 
5/7/2015    6 
5/7/2015    1 
5/10/2015    9 







Table 2 -Schedule of Interviews/Questionnaires Surveys (Patients) 
 
Date         Patients (PT)       
             
5/22/2015    1 
6/17/2015    2 
6/17/2015    3 
6/17/2015    4 
6/17/2015    5 
6/17/2015    6 
6/17/2015    7 
6/17/2015    8 
6/17/2015    9 
6/17/2015    10   




 This research performed an inductive data analysis of collected raw data that consisted of 
transcription, coding the data, placing data into categories and reducing data to themes and sub-
themes.  The purpose of this is to condense textual data, establish clear links among research 
objectives and to summarize findings (Thomas, 2006). I utilized constant comparisons, sought 
concepts, themes and experiences of the raw data using open and selective coding (Charmaz, 
1990). I manually coded the data to develop themes by extensive comparison of the data.  I 
looked for patterns, similarities, and contrasting answers that would address the three research 
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questions.  Selective coding was used to establish a core variable.  Codes were then transferred to 
themes and sub-themes that I found to be more salient.   
 Axial coding aided this process and allowed for an open coding category to generate a 
“core phenomenon” (Creswell, 2007, p. 66).  And it allowed for the data to create categories 
around this phenomenon (Creswell, 2007). I addressed and answered three research questions in 
this exploration developing semi-structured open-ended questionnaires/interviews of 
participants; these relationships of the results that emerged from data collected will be discussed 
in subsections that will follow. 
Interviews/Questionnaires 
 Ten providers responded to five questions, and 10 patients responded to 10 questions.  
The collection of data consisted of electronic mail responses, phone interviews and face-to-face 
interviewing.  I coded all data with open- ended coding by segmenting all interview questions 
that addressed and answered each corresponding research question. Table 3 indicates succinct 
answers to the interview questions and shows the corresponding research questions for patients; 










Research Question 1 
  Interview Questions PT1, PT2, PT3, PT4, and PT5 answered Research Question 1: Does 
reimportation prescription drug policies contribute to patients’ drug adherence? Overall, the 
answers to questions IQ1, IQ2, IQ 3, IQ4, and IQ5 demonstrated a positive perception for 
reimportation policies and a positive contribution to medication adherence. In response to IQ1 
(40%) of the 10 participants felt drugs from the Canadian market are safe; while (30%) have 
some reservation about drugs from non-United States markets. PT7 stated “I am concerned about 
the ingredients in the medication” and PT10 had concerns about expired drugs and counterfeit 
drugs.  PT3 stated: “United States drugs only” was her preference and PT5 had concerns of drug 
abuse from these markets.  When I further probed about his drug abuse statement he stated that 
the “cheap cost” could cause the abuse. 
 IQ2: What concerns do you have if you are unable to take your medication? Seven (70%) 
of the 10 participants are concerned about their current medical condition worsening when they 
are unable to take their medication with 30% fearing death. PT1 was also concerned with being 
placed in a nursing home. Only 10% of the patients are concerned on how to obtain and pay for 
the medication. PT4 is concerned with side effects. 
 IQ3 answers demonstrated that 40% were experiencing savings or expected to save 
money with the reimportation policy in place.  PT2, PT4, PT8 stated “no cost savings at this 
time” because of current medication insurance that only utilizes the United States pharmacies. 
The stated these insurance companies “pays all cost” or (as stated) by PT2 “I have a very low co-
pay.” In response to IQ4, eight of the participants stated a positive response to “if cost were not a 
factor”. PT1 stated: “would be a great thing.” PT2, PT6 and PT8 stated “would be able to take 
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prescription.” “Would feel better” was the response from PT4; while PT9 responded “best 
thing!” “Devastating if cost was a factor” responded PT10. Only PT3 stated there would be “no 
impact”. PT5 responded: “this could be a double edge sword”, after follow-up questioning he 
states it could be “good and bad”. 
 In response to IQ5: Please explain if cost has or has not affected your ability to follow 
your drug regimen? Cost is affecting or has affected patients’ ability to obtain and take their 
medication; 40% of the patients stated this. PT9 stated that cost has affected her because she 
“lives pay check to pay check”. Insulin cost is unaffordable for PT5 she responded “I can’t 
afford my insulin without the reimportation policy.” PT2 responded “that paying anything for 
medication out of pocket is a concern.” Forty percent of other patients say cost is not a factor 
because of current insurance from job or state.  PT6 (a cancer patient) gets all her medications 
from Canada and stated “cost is not a factor because of the Canadian market.”   Past cost was an 
issue for PT8 but not anymore because as he stated “it is not a problem now since I cross the 
border.” 
Research Question 2  
  Interview Questions (PT6, PT7, PT8, PT9, and PT10 answered Research Question 2: 
What perceptions do patients have about reimportation drugs as related to a chronic disease?  
IQ6 had a response of 50% that are favorable towards safety of Canadian pharmacies. PT1 stated 
“safe because of Canada’s reputation”.” PT7 and PT8 responded with “possibly” and “not sure” 
respectively. PT4 and PT10 stated “not safe” because of “incorrect chemical compounds” and 
“no” because “I just don’t know the pharmacy.” 
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       IQ7 had a 50% positive perception of the reimportation policy and obtaining drugs from 
Canada in comparison to the United States markets. The understanding of the reimportation 
policy varies.  All patients were aware of the ability to use the Canadian market.  I interpreted the 
Canadian market and the United States market to be on an uneven playing field. PT1, PT2, PT3, 
PT5, and PT8 responded favorably.  PT1 responded: reimportation that allows for Canadian 
drugs are “safe and affordable” in comparison to the United States local markets. PT2 believes 
“drugs are the same” as the United States drugs. Although it takes a little longer to receive, it is a 
“good once I receive them” stated PT5. Twenty percent stated unfavorable answers; PT10 
understanding of non-United States markets is that all drugs come from undeveloped nations and 
that “Americans should stay away from them”. PT6 is a cancer patient who consumes a 
$2000.00 drug every month (if purchased in the United States) for her cancer treatment.  But she 
gets her medication from Canada (every month) for only $30.00 co-pay.  Thus, her 
understanding is that “doctors and officials are not helping citizens, and those costs are 
controlled by the government”.   
 In response to IQ8: patients’ preparation for future use of the policy and the Canadian 
market indicated 40% will consider using the Canadian market to obtain medication; to allow for 
adherence of their regimen. PT1 responded “will use Canada drugs.” PT4 and PT9 stated “would 
consider cheaper market”. PT3, PT5, and PT8 indicated no preparation for long term use as it 
relates to their medication. PT7 and PT10 preparation is to “use United States drugs only”. PT2 
states she will continue ongoing consultation with her physician to see what is best for her. 
 IQ9 indicated (60%) of patients are not consulted by their health care providers on 
affordable drugs and how these affordable can increase adherence. PT3, PT6, PT7, and PT9 were 
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the only patients who stated they are consulted on affordable drugs. Generic drugs were the 
affordable medication options given to PT3 and PT7 by providers.  Consultation for using 
reimportation drugs from non-United States markets were not mentioned by any provider.  In 
response to IQ10 concluded with nine patients 90% indicating that purchases from international 
markets are not applicable in relationship to the total management of their current disease.  After 
follow-up questioning, the majority of answers demonstrated that there is no way to link 
exclusively the international markets solely to disease management.  Their drug purchases are 
inter-mixed with drug purchases from the United States. One exception to this is PT6.  Recall, 
PT6 gets her $2000.00 medication from Canada for $30.00 co-pay thereby, management of her 
disease is greatly increased and the reimportation policy has helped. 
Research Question 3 
  Interview Questions (PR1, PR2, PR3, PR4, and PR5) addressed and answered Research 
Question 3: What are the perceptions of key providers (physicians, nurse practitioners, and 
physician assistants) regarding the impact of re- importation drug laws on patient medication 
adherence? The overall answers for all interview questions from the providers demonstrated a 
positive/good optional program. Providers responded (100%) favorable that the policy can 
improve patients’ adherence.  PR1 and PR5 responded “cheaper drugs, they will take” PR3 
responded “the Canadian market helps to stay on meds.” “Much likely to stay on prescription” 
stated PR4.  Access to affordable drugs helps many of my patients” stated PR6. PR9 
responded:”patients will stop taking medication if cannot afford”. “More likely to obtain if cost 
is less as in Canada” stated PR10. 
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    IQ2 answers indicated that (100%) of the providers feel discussing medication adherence is 
important at every visit.  Words such as “always”, “each visit”, every visit” and “during regular 
visits” were used. The majority of focus (70% of providers) stated that during consultation, the 
focus was on taking the medication and if not taking, then why? PR2 states that education about 
the medication was a main focus in consultation about adherence. Other answers were “dose 
verification”, “safety”, and “side effects” were topics of conversations when speaking about 
adherence. 
     IQ3 responses demonstrated a positive response from 80% of the providers stating that the 
policy will have a positive effect on adherence levels. PR4 and PR9 were the only participants to 
state that “it is too soon to tell” of any effects from the policy. 
     Providers stated words such as “ helpful”, “affordable”, “makes a big difference”, “will have 
an effect” and “would provide a good option”, and “affordable drugs a big help”.  PR1 stated 
“that a policy is not going to change people mindset they will continue to cross the border here in 
Maine for medication it was going on before the policy and will continue.” 
     Provider’s ability to monitor patients’ health solely based on where drugs are purchase is a 
difficult task. Thereby, 80% of the providers stated that they don’t know of any direct link to 
adherence of the policy at this time. Answers such as “can’t say” and “have not noticed any 
major changes” were given. Provider’s response to IQ5 exhibited favorable perception to the 
benefits of the reimportation policy.  They (providers) stated “ cheaper”, “reputable”, 
“reasonable cost”, “medication for less”, “helpful because of cost”, and “competitive “. PR7 was 
the only provider to state “not sure yet.” IQ5 elicited some concerns from providers as they 
stated “the legality and extra effort is needed” also “quality assurance and safety could be an 
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issue” stated PR4, PR8 and PR9. PR2 stated that the “lack of effort to big Pharma to make meds 
affordable is not there.” 
Themes 
 Diagrams to demonstrate and organize the relationship of concepts, themes and 
categories are important (Corbin & Strauss, 2008). Constructing theories though concepts can be 
generated in many different ways; the relationships are based on the data obtain and is grounded 
in the data (Corbin& Strauss, 2008). Therefore, I developed three diagrams to demonstrate the 
relationship between dominant themes and subthemes that were influence from constant 
comparing and analyzing the raw data.  Figure-1 corresponds with themes related to the 
providers; Figure-2 corresponds with themes related to patients’ responses and Figure-3 is 




































Providers’ Theme 1: Dominant Theme 
  Contribution to increase adherence level: Providers demonstrated overall that a 
reimportation policy contributes now and can contribute in the future to adherence levels 
positively. This theme emerged from IQ1, IQ3, and IQ5. In answer to IQ1, what asked: Describe 
how this policy can improve patients’ adherence? Seven providers (70%) stated adherence will 
increase because “patients are able to obtain and take medication” and “Canadian market helps”. 
Other statements followed such as “cost is a factor, more likely to take them” and “will take 
advantage of affordable drugs.” My interpretation is that affordability is the incentivized driving 
force. 
Providers’ Theme 2 
   Affordable drugs/cost effective: Providers indicated that cost is a factor and a major 
cause why patient will seek these drugs and thus take them.  This emergent theme comes from 
IQ1, IQ5. Providers responded to IQ1 with “cheaper”, “less expensive”; IQ5 answers elicited 
“lower cost” and “reasonable cost”. 
Providers’ Theme 3 
 Reimportation Overall effect: IQ3 and IQ5 demonstrated an overall positive response. 
IQ3 asked how this policy affects patients’ adherence; five providers responded favorably stating 
“more likely to adhere” and “a good option.” IQ5 demonstrated favorable answers; when asking 
providers to describe the pros and cons of this policy long term, three providers stated “helpful 





Providers’ Theme 4   
 Drug Safety/Quality Assurance:  Forty percent of the providers demonstrated a positive 
safety response as emerging from IQ5.  Responses included “reputable” and “no concern for 
safety coming from Canada.” 
Providers’ Theme 5 
   Consultation/Education:  This theme emerged from IQ2. All providers stated that 
consultation and education of drugs were very important; and the importance of adherence is 
discussed at “every visit”, “each visit” and “always” stated providers. 
Providers’ Theme 6  
  Unaware of policy: This theme emerged from IQ4 as two providers were unaware of the 
policy but have patients that cross the border to secure drugs. PR1 stated that “no policy matters, 
they will still get meds with or without a policy from Canada.”  These two providers’ answers 
stood out because it indicates that 20% of the providers are unaware of a policy that can help 
their patients. My interpretation is that increase communication and education are mandated. 
Provider’s Theme 7   
 Positive effects on current condition: Providers indicated that IQ3 answers to current 
conditions were helping with the use of the Canadian market. PR4 stated “yes and a few people 
outside my area are getting meds from Canada.” PR3 responded “we need similar pricing here in 
the United States”, makes a “big difference” stated PR2. Other favorable responses were “would 





Patients’ Theme 1: Dominant Theme 
  Potential Adherence: Patients demonstrated a positive perception for reimportation of 
current and future adherence.  This theme emerges from IQ1, IQ3, IQ4, IQ6, and IQ8. In 
response to IQ1 and IQ6: What concerns (if any) do you have or have had about medication drug 
purchases from non-United States markets:  forty percent of participants stated no concerns and 
feel drugs are safe and 20% stated “possibly”. Four patients say they are saving money and 
expect to save money (in response to IQ3). In response to IQ4, 90% stated adherence would 
increase if cost were not a factor. IQ8 answers yielded a 30% positive response for future use of 
Canadian markets, 30% stated they have no idea about what to do for future preparations. And 
20% responded they will stay exclusively with United States pharmacies. 
Patients’ Theme 2 
  Consultation/Education: This theme stemmed from IQ6, IQ7, and IQ9.This theme 
emerged from answers and follow-up questioning from participants. My follow-up questioning 
leads me to intrepid that patients do not completely understand reimportation protocol. These 
drugs are manufactured in the United States and shipped out to other nations and then returns to 
the United States. In response to IQ6: Do you feel drugs are safe? Twenty percent stated “no” 
and 20% stated “possibly” or “50/50 chance they are.” But 40% responded favorable to safe 
drugs from Canadian pharmacies. IQ7 answers yielded several variances to the question of how 
do you perceive the overseas drugs in relationship to local drugs? PT3 and PT4 responded 
“none”, PT1and PT8 stated affordable and “cheaper”. Other answers included PT2 respond that 
he understands “drugs are the same as United States” and 20% of patients (PT7 and PT10) 
responded that they will use only United States drugs.  I interpreted additional education on the 
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topic could renderer increase favorable answers. In response to IQ9: Eighty percent of patients 
stated that they are not given information to seek more affordable medication from their health 
care provider. My interpretation is that additional education to providers is also needed for them  
Patients’ Theme 3 
 Cost Effective: Several patients stated that cost is a driving force for taking their 
medication now and the future. This theme emerged from IQ3, IQ5, IQ7, and IQ8. The answers 
for IQ3 are you experiencing cost savings or expect to save money: demonstrated that 40% of 
patients are saving or expect to save because of the reimportation policy. Six patients gave 
various reasons why they are not saving on Canadian drugs mainly stating that current 
employment insurance or Medicare is covering all prescription cost. Patients in IQ5 
demonstrated that 40% of patients stated cost has a direct link in their ability to follow 
medication regimen. Fifty percent of patients stated no direct effect of management of their 
disease because of reimportation drugs; there is no exclusivity on Canadian market and drug 
purchases for current disease consist of United States’ pharmacies as well. Thirty percent of 
patients stated “affordability” and “less expensive” answers when contrasting the United States’ 
pharmacy markets. Other patients’ answers suggested “additional research is needed” and “only 
United States medication” was preferred by one patient. In response to IQ8: Forty percent of 
patients stated that cost will be a factor in the future for adherence to drug regimen, and they will 
consider the Canadian market. 
 Patients’ Theme 4 
  Drugs are safe: This theme emerged from IQ1, and IQ6. In response to IQ1, What 
concerns do you have about medication drugs purchased from non-United States markets? Four 
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patients stated they had no concerns, and with one patient stated “drug abuse”; while another 
patient is concerned with “counterfeit drugs” and “cutting corners.” IQ6 asked: do you feel drugs 
are safe from these pharmacies (overseas) if so why and what concerns do you have (if any)?  
Forty percent stated “yes” two other patients responded “possibly” and one patient stated “not 
sure.” 
Patients’ Theme 5 
  Reimportation policy helps to manage current condition: This theme emerged from IQ10 
that asked: How has reimportation policy help you to manage your disease? Only one patient 
(PT6, who exclusively gets her meds from Canada) responded positively on this question. One 
other patient stated “this is a good option”. The remaining patients 80% stated that there is no 
link to the policy and management of their current disease. Upon follow-up with these patients 
the majority responded that there is no way to exclusively (directly) connect the policy and 
Canadian drugs (to their management) when they also get medications from the United States. 
Patients’ Theme 6 
  Current Condition Concerns:  This theme emerged from IQ2 that asked what concerns 
you have if you are unable to take your medication. All patients (100%) stated that their inability 
to take medication is a big concern and will seek alternative therapies to get their medicine.  
Three patients stated “death” as a concern, and seven patients are concerned with current 
condition worsening. 
Patients’ Theme 7 
  Future use of Canadian Market:  This theme was created from IQ8. Four patients 40% 
are prepared to use the Canadian as a primary and supplement market for their future needs; they 
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stated cost as the reason. Three patients (30%) have no idea about their plans for future use and 
two patients 20% will continue to stay with the United States markets only. 
Discrepant Case 
 Researchers should make every effort to locate discrepant cases (Merriam, 2002). This 
research study invited 20 participants (10 providers, and 10 patients).  PT3 did not completely 
align with answers from other participants. This participant’s initial answers were short and only 
stated his “allegiance” to American products.  Many of his answers were “United States only!” 
for questions that did not warrant such answers. Further probing and questioning of this 
participant yielded a minimum additional clarification and understanding (but not much). 
Conclusion 
 The findings in this research emanated from responses to interview questions observed 
for a 12-week period. Ten health care providers and 10 patients were invited to participate in this 
research that explored the perceptions of providers and patients in relationship to medication 
adherence levels and reimportation of prescription drugs. The answers from this three month 
long study demonstrated that health care providers and patients in the state of Maine have a 
positive perception of reimportation, and that said policy can contribute to increasing drug 
adherence that is incentivized by affordability.  
 Although additional education and discussions are needed, participants’ answers reflected 
a favorable perception on the subject. At this juncture the playing field is not even when 
contrasting medication drugs from the international market and the United States markets. Media 
attention, advertisements and further understanding of reimportation must become more 
83 
 
equivalent for reimportation drugs, until then, it is my conjecture that favorable responses are not 
maximized. 
 This chapter outlined the population that took part in this exploration, how participants 
were protected, the role of the researcher, and the procedures utilized to ensure the quality of raw 
data collected. Also detailed was how data was collected, and methods used to analyze the data.  
Chapter five will summarize the finding of this study. I will discuss the relationship of the 
findings to the theoretical framework, a make inference to conclusions, briefly discuss 

















Chapter 5: Summary, Conclusion, and Recommendations 
Introduction 
 The need for supplemental, affordable medication programs, and policies has been a 
growing topic within the health care arena.  Patients’ adherence levels of many chronic diseases 
continue to plague the medical field with growing distinction, soaring monetary costs, and 
illnesses.  Health care officials for many years have debated the effectiveness and safety of 
reimportation drugs. This study went into the field to see what patients and health care providers 
have experienced; and to capture their thoughts, opinions, comments, experiences and listen to 
their voices.  Providers who prescribe these medications have a role and voice in this matter as 
well.  I wanted to see what these providers who are on the “front line” every day have to say 
concerning adherence levels and reimportation drugs. They are helping to change the plight of 
their patients through consultation and prescription drugs and any improvement to the health care 
system can aid this process. 
 It is very important to identify the components that can aid patients in the development of 
good, effective and solid policies. I expected only veracious answers from each participant and 
did not form any opinion prior to engaging in the research. My total commitment was to allow 
the results to yield a conclusion. Participants approached me and the study in a welcoming 
manner.  The people of Maine displayed a level of sincerity to this topic by responding positively 
to me and the study. Interpretation of findings for the study, the conclusion, implication for 





Interpretation of Findings 
 I conducted the study in the state of Maine where citizens are allowed to purchase 
prescription medication from non-United States pharmacies.  In Maine, the reimportation market 
is better known as the Canadian market.  Although the reimportation policy allows for purchases 
from United Kingdom, New Zealand, and Australia, Mainers (people from Maine) can relate to 
only the Canadian market; this was a realization from the pilot study.   
 The design of the study was qualitative with a grounded theory approach. The purpose of 
the study was to see if reimportation policies have an effect on patients’ adherence levels. Three 
research questions were developed to 15 interview questions to gain insight of health care 
provider’s and patients’ perceptions. The research questions were answered by analyzes of 
participant’s answers to open-ended interview questions within a natural setting. Ten patients 
and 10 providers responded to 10 questions and five questions, respectively. Data collection for 
this study used member checking to add credibility to the research. 
Limitations of the Study 
 Within every endeavor there exist shortcomings; within this study one limitation is the 
fact that only one state has a reimportation law. Also, the majority of Maine’s population is 
Caucasian descent. These factors limit the research as other ethnicities are not fully represented.  
Although this research did have two minority patients participate, the overall make-up of the 







Research Question 1:  How does a reimportation prescription drug policy contribute to patients’ 
drug adherence? 
 Patients’ answers demonstrated a positive outcome to this question. In response to IQ4: 
Can you describe the impact of your taking your medication (as prescribe) if cost were not a 
factor? Patients stated that reimportation of drugs had contributed to obtaining medication and 
taking them. The words used by the various participants included “much likely to stay on meds,” 
Canadian market helps to stay on meds,” “if cheaper, able to take meds”, “affordable medication 
a big help”; along with “helpful”, “will have an effect”, and “more likely to adhere.”  PT5 
responded to IQ5 that asked: please explain if cost has or has not affected your ability to follow 
your drug regimen? His response was “yes otherwise I cannot afford my insulin.” The responses 
to the interview questions demonstrated an overall positive perception to reimportation policies 
and increases drug adherence.  Many patients (40%) demonstrated no concerns about medication 
coming from the Canadian market.  Additionally (40%) of patients are very concern if they are 
unable to take their medication and fear worsening of their current disease stating that affordable 
medication can resolve this issue. 
Research Question 2: What perceptions do patients have about reimportation drugs as related to 
a chronic disease? 
  Another focus of the study was to explore the perceptions of patients about reimportation 
policies and adherence levels. Participants (overall) demonstrated a clear perception of this topic 
with favorable an answer. Patients’ answers consisted of “safe”, “affordable”, “drugs are the 
same as the United States”.  Patients indicated they would use the Canadian markets for future 
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medication needs to remain adherence.  A two patients indicated “not sure”, or “possibly” to IQ6 
that asked: do you feel the drugs from these pharmacies (Canada) are safe? Based on answers 
from IQ7, I interpret that they do not have a full understanding of the non- United States markets 
pharmacies and the reimportation protocol. Other responses were “should stay away from it”, 
from PT10 response and “better if local markets are used” as stated PT7.  The answers to the 
interview questions revealed that all patients experienced elevated levels of perception of 
reimportation policies and drug adherence. 
Research Question 3: What are the perceptions of key providers (physicians, nurse practitioners, 
and physician assistants) regarding the impact of re- importation drug laws on patients’ 
medication adherence? 
 Providers in the state of Maine who prescribe medication were invited to participate in 
this study.  The answers indicated a positive, clear perception. Most of the providers indicated 
that affordability is the incentive that would have patients adhering to their medication.  For 
example, words such as “cheaper,” cost is a factor,” and “less expensive” were used. IQ3 (PR): 
How does this policy affect patients’ adherence levels? Seven out of 10 providers responded 
positively to increase adherence to this policy. Providers responded well to safety and quality 
assurance. PR5 responded that this policy “provides a good option.” Providers also agree that 
future use of reimportation will enhance the adherence levels of their patients; words such as 
“increase access to drugs for less, will increase adherence.” I encouraged all participants to speak 
freely and to give their true feelings and experiences. 
 Responses to the three research questions confirm the theoretical framework on which 
this study is based; Kurt Lewin’s organization change theory; unfreeze, change, and refreeze 
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(Lewin, 1947).  Although originally presented many years ago, it is still relevant today. The 
theory’s first model (unfreeze); involves getting to a level of understanding that change is needed 
and preparing to move away from status quo. The second model (change or transition); defines 
the journey of movement that is made to changes. And finally refreeze; this is about getting to a 
stability point once the changes have been made. The changes are understood and accepted by all 
thereby, becomes the new norm (Lewin, 1947).  The themes that resulted from participant’s 
answers are outlined below: 
 Research Question 1: Does reimportation prescription drug policies contribute to patient 
drug adherence? 
Themes:  
 Patients felt adherences were contributed due to the affordability and the reimportation 
policies. 
 Patients are experiencing cost savings. 
 Patients thought the impact of reimportation policy was a good thing. 
 Patients felt that not being able to take meds would worsen current state and would look 
to non- United States markets to obtain. 
 Research Question 2: What perceptions do patients have about reimportation drugs as 
related to a chronic disease? 
Themes: 
 Patients felt cost had affected their ability to follow drug regimen. 
 Patients felt (overall) that drugs are safe from non-United States markets. 
 Patients have a good understanding of drugs from Canada in contrast to the United States. 
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 Patients stated that they would utilize the reimportation policy in the future. 
 Patients felt that consultation and education about affordable drugs were not given by 
providers. 
 Patients stated that no direct impact on disease management on reimportation policy. 
 Research Question 3: What are the perceptions of key providers (physicians, nurse 
practitioners, and physician assistants) regarding the impact of reimportation drug laws on 
patients’ medication adherence? 
Themes: 
 Providers stated drugs were affordable and this equates to adherence. 
 Providers stated adherence consultation is given each visit. 
 Providers can’t state any direct improvement due to policy. 
 Providers (overall) stated the safety of drugs was not a concern from Canada. 
 This research demonstrates that non-adherence and cost are problems (unfreezing). 
Attention is needed to address the problem (change/transition), and new policies are needed to be 
implemented (refreezing). This organization theory applies to the entire nation and new policies 
(reimportation) should be considered on a national scale. 
Recommendations for Further Study 
 This research utilized a convenience sampling of 20 participants all over the age of 18 
years old. Similar and different studies should be conducted among a larger population.  Studies 
can look at specific chronic diseases or continue to focus on multiple chronic diseases as it 
relates to adherence levels and reimportation of prescription drugs. 
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 I conducted the study over 12-weeks.  I recommend that multiple longitudinal studies 
could benefit this research and is recommended to understand further if longer studies (with a 
significant amount of participants) would change the outcome of perceptions. Continued focus 
studies of medication adherence levels should carry on along with specific studies of 
reimportation concerns. Larger populations within and outside the state of Maine would benefit 
future research on this topic.  Several states are considering a new order of federalism (system of 
government in which the same territory is controlled by two levels of government, 
Cornelllaw.edu, 2014) and implementing their reimportation policies; the majorities of these 
states are in the same region as Maine and have a close proximity to Canada. Once implemented, 
studies in these states can possibly contribute to the subject matter. 
 I also recommend the continued education of reimportation policies protocol to the 
citizens for whom it is intended for. Officials should continue to education health care officials to 
this subject matter in both rural and non-rural areas; all health care providers should know that 
such affordable markets are available for their patients. 
Recommendations for Action 
    Political and health care officials who take on the authoritarian role within the health 
care arena have the responsibility to implement policies that can benefit the general population. 
These individual (officials) should consider the findings of this research when engaging new 
policies related to this topic.   
 Because many individuals have a chronic need for affordable drugs program, planners 
should be willing to break new ground and go against traditional methods and policies seen in 
the past.  Many of these methods are not sufficient and require additional support and funding.  
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This study demonstrates that providers and patients see a benefit in reimportation policies and 
indicates an increase in patients’ medication adherence with the aid of reimportation policies; 
this could contribute to the change of plight for many Americans desperately seeking help. The 
finding within this research should be considered. 
 The monetary value (savings) that this policy can have on a national scale is tremendous 
thereby, the components of this exploration should be included when discussions are underway.  
According to Brown and Bussell (2011), patients with chronic diseases, account for 
approximately 50% of non-adherence. This level of adherence leads to increase morbidity and 
death.  And has an estimated $100 billion per year in costs; reimportation policies can reduce this 
cost significantly. 
Implications for Positive Social Change 
 According to a study by Medco Health Solution data in 2008, it indicated that 51% of 
(Americans) children and adults were taking one or more prescribed medication drugs for a 
chronic condition. This indicated an increase from 50% from 2004-2007 and 47 percent in 2001. 
Medco examined prescribe medication records from 2001 to 2007 from a registry sample of 2.5 
million customers (children to the elderly) in their database. Chronic medication consumption 
concerned areas were seen in all demographic groups. Two-thirds of women 20 years and older; 
one in four children and teenagers, 52% of adult men, and three out of four people 65 years or 
older. Among senior citizens, 28 % of women and 22% of men take five or more prescribe drugs 
regularly (Medco.com, Retrieve 2015).  
 This research can contribute to an entire nation. Prescription medications are the most 
significant health care product to society.  Everyone at some point will be affected by 
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prescription drugs. And with increase life longevity many individuals will have a need to be 
medicated at some point. Continued discussions of reimportation and adherence levels should be 
taken very seriously. A dual process is being undertaken.  First, patients are more likely to take 
medication if cost is not a factor, and second, in doing so, a significant saving to patients and the 
(health care) insurance industry ensues.  
 PT6 of this research is a good indication that this research is needed and that 
reimportation policies are contributing to increasing adherence thus, saving lives.  Recall, PT6 
must have a $2000.00 cancer drug every month (that she only pays $30.00 in Canada). And 
without the reimportation policy this much-needed drug would not be available.  Likely, without 
the medication it would contribute to a worse state, leading to death.  This research and other 
research on this topic are for all the PT6 in the nation who need a voice.  The economic savings 
to health care insurance companies along with savings to patients could yield additional funding 
that can be repurposed to other health care issues such as research on various diseases. 
Researcher’s Personal Reflections 
 I commenced my study in Public Health Policy because of several reasons.  I often have 
seen family members and friends suffer from not having the resources to purchase drugs 
monthly.  They often had to make the tough choice of paying for prescription medications or pay 
other monthly bills. In medical school, I was so often saddened to see prescriptions written for 
patients who later will return 6 weeks later for a follow-up appointment, only to indicate that the 
prescription was never filled.  Many times the patients would pull out the now faded, wrinkle 
prescription and say “I can’t afford it doc”.  We (as health care providers) often give out samples 
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to aid this process but only so much can be done; other programs are needed to supplement the 
efforts of  prescription adherence.  
 This research demonstrates that reimportation legislation should be highly considered. I 
feel that maximum benefits of a reimportation law will be seen with the extremely costly drugs.  
The average patient may not see elite benefits with some existing drugs that are cheaper (as in 
generic) and that are readily available anywhere in the United States. But that is not to say that a 
reimportation law may not help the mass, I believe it will. So much research on this matter is 
needed and the discussion should (in my opinion) remain in the forefront of health care officials 
and lawmakers throughout the nation. Reimportation policies cannot be a “savior” for all drugs 
and, for this reason, the research recognizes that reimportation does have some shortcomings. 
Conclusion 
 The literature review of the research has disclosed inadequate research data for 
reimportation policies and the impact on patients’ drug adherence.  The literature review also 
voids the voices of providers and patients in this regard. Rhetoric from politicians and 
pharmaceutical companies display a proclivity for profits and not the voice of the people. There 
exist gaps in the literature to address reimportation and any contributions to drug adherence in 
the United States. 
 Although supplemental programs such as Medicare exists, and there is assistance from 
pharmaceutical companies to help patients (such as sample medications), this does not suffice to 
address adequately the problem. No one “fix” will aid patients in this endeavor; it will take the 
continued efforts of many organizations and officials to passionately help resolve this issue.  
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Reimportation can be one of many tools used to combat the problem of non-adherence, and 
should seriously be considered on a national scale. 
 Events in recent months in the state of Maine (I feel) substantiated the need for this 
research and further research on this topic is required. In February 2015, United States District 
Judge Nancy Torresen struck down the Maine Pharmacy Act that allowed Maine residents to 
purchase lower-cost prescription drugs from Canada, the United Kingdom, New Zealand, and 
Australia via a broker.  According to the judge’s 19-page ruling, the Food and Drug 
Administration (FDA) has jurisdiction over the importation of all medications (Silverman, 2015).  
Thus, at this juncture, of this study there exists no one state that has a reimportation law.  But as 
stated by one of the providers (PR1)of this study “patients will continue to get medication from 
Canada with or without a policy.” Advocates for reimportation are in discussion to see if an 
appeal is in order. 
 This study has reflected that providers and patients see reimportation as a tool that can 
contribute to higher levels of medication adherence. This research is not suggesting that 
reimportation policies completely replace existing programs that are in place. But, considerations 
for reimportation to be reinstated in Maine and to be a top consideration for all other patients 
(throughout this country) who voices have gone unheard. It is the duty of a nation to adhere to 
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 Demographic Profile 
 
In addition to interview questions, the following questions were asked of all participants in 





 Age (range)? 
 Smoking? 






















Dear Prospective Research Participant, 
 
I am Jeffrey Tubbs; a PhD candidate in Health Services at Walden University, conducting a research 
study related to one component of patient non-adherence of prescription drugs and I am investigating if 
reimportation of prescription drugs has an effect on patients’ drug adherence levels among participants 
who have a chronic disease.  
 
I am seeking participants to interview (face-to face) who speak English fluently and have a chronic 
disease that requires monthly renewal prescription refills (on-going refills). Participants of the age of 18 
years old and older are welcomed. Previously purchases of prescription medication from outside the 
United States (such as Canada) are desired. The interview time span may last between 10-15 minutes.  
At any time during the interview, the research participant may withdraw if he or she feels uncomfortable 
with the content of the interview protocol. 
 
This research is not affiliate with this medical institution; your participation or non-participation will not 
have any effect on the treatment you receive or the relationship you have with staff members. 
 
If you are interested please contact me via the below listed information.  This research will make every 
effort to conform to Health Insurance Portability and Accountability Act (HIPAA) in that all information 





Jeffrey Tubbs, MD, MBA, BSc. 










The following research questions (RQ1) corresponds to the following stated interview questions: 
 
RQ1: How does a reimportation of prescription drug policy contribute to patients’ drug 
adherence?  
 
Interview Questions  
 
1. What concerns (if any) do you have or have had about the overseas drugs?   
2. What concerns do you have if you are unable to take your medication(s)? 
3. Are you experiencing cost savings (from overseas purchases) of your drug medication 
purchases (please explain why or why not)? 
4. Can you describe the impact of you taking your medication (as prescribed) if cost was not a 
factor? 
5. Please explain if cost has or has not affected your ability to follow your drug regimen? 
------------------------------------------------------------------------------------------------------------------- 
The following research questions (RQ2) corresponds to the following-stated interview questions: 
 





6. Do you feel the drugs from these pharmacies (overseas) are safe if so, why and what 
concerns do you currently have (if any)? 
7. How do you perceive the overseas drugs in relationship to local drugs for long term health? 
8. Chronic diseases are long term decision process; describe your preparation for this as it 
relates to your medication drug choices? 
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9. Are you given optional advice to seek more affordable medication from your physician, if so 
what options were suggested? 
























Providers Questions (PR-Q) 
 
 The following research question (RQ3) corresponds to the fore-stated interview questions: 
 
 RQ3: What are the perceptions of key providers (physicians, physician assistants & nurse 




1. Describe how this policy (can) improve patients’ adherence? 
2. How often do you consult patients about adherence of drug prescriptions? 
3. How does this policy affect patient adherence levels or is it too soon to tell? 
4. Describe any improvements with your patients’ adherence since this policy has been in 
place? 
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Researcher: Jeffrey Tubbs, MD, MBA (College of Health Sciences) 
   
Based on my review of your research proposal, I give permission for you to conduct the study entitled 
“Public Policy De Facto, New Order of Federalism: Re-importation of Prescription Drugs, a Major 
Factor to Patient Drug Adherence” (3.)within_____________________.  As part of this study, I 
authorize you to conduct a full interview session with participant(s) and myself. Individuals’ 
participation will be voluntary and at their own discretion.  
 
We understand that our organization’s responsibilities include: a small room that the partner will 
provide. This (institution/individual) reserves the right to withdraw from the study at any time if our 
circumstances change.  
 
I confirm that I am authorized to approve research in this setting and that this plan complies with the 
organization’s policies. Recruitment of participates (patients and physicians) are granted and they have 
the right to deny any participation of the research process. 
 
I understand that the data collected will remain entirely confidential and may not be provided to anyone 
outside of the student’s supervising faculty/staff without permission from the Walden University IRB.  
This research under-taking has been approved by Walden University Institutional Review Board (IRB) 







(4).Authorization Official (signature) __________________________________ 
----Hand signature----   or ------- 
--------The use of your email can be used to sign this document electronically-------- 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
